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ABSTRACT 
Chintan H. Kapadia: Engineering PRINT® Nanoparticle Subunit Vaccine to Induce Antitumor 
Immune Response  
(Under the Directions of Joseph M. DeSimone) 
 
Educating our immune system via vaccination is an attractive approach to combat 
cancer. Tumor-specific cytotoxic T cells (CTLs) such as CD8+ effector T cells play a critical role 
in tumor control. However, vaccination aimed at eliciting a potent CD8+ T cell response with 
tumor-associated peptide antigens, are typically ineffective due to poor immunogenicity. 
Nanoparticle delivery of antigens and adjuvants can enhance their uptake by antigen presenting 
cells (APCs) and facilitate their intracellular delivery to induce antigen specific CD8+ cells. 
PRINT® (Particle Replication in Non-Wetting Template) is a unique platform to fabricate nano 
and microparticles with exquisite control over size, shape, and surface chemistry. The goal of 
this study is to design a PRINT® nanoparticle based subunit vaccine for the intracellular delivery 
of antigenic peptides and adjuvants to induce potent CTLs response.  The aims of project 
include, i) formulation design of nanoparticle subunit vaccine, and induction of ii) in vitro and 
in vivo immune response.  
Under the first aim of this study we have engineered a reduction sensitive PRINT® 
hydrogel based subunit vaccine for intracellular delivery of antigenic peptide SIINFEKL 
(ovalbumin-derived CTL epitope [OVA257-264 –SIINFEKL]) and an immunostimulatory 
adjuvant, CpG ODNs (TLR9 agonist). SIINFEKL and CpG ODN were conjugated to PRINT® 
hydrogel via disulfide linkages. These NPs were successfully internalized and processed by 
BMDCs, resulting in BMDC maturation, subsequent cross-presentation of antigenic peptide, 
and induction of potent antigen-specific T cells in mice. Under the second aim of this study we 
further demonstrated induction of SIINFEKL specific IFN-γ producing CD8+ T cells as well as  
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antitumor protective immune response in EG7 tumor mouse model by delivering sustained 
release formulations of CSIINFEKL and CpG ODN via PRINT® hydrogel NPs. Taken together, 
this study provides a highly effective approach, i) to induce potent CTLs response by reduction 
sensitive NP subunit vaccine and, ii) to induce antitumor immunity by tuning the release of 
antigenic peptide by changing the conjugation chemistry. 
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Chapter-1: Cancer Vaccine- A Type of Immunotherapy* 
1.1. Introduction to tumor immunobiology 
1.1.1 Innate/adaptive immunity 
The immune system fights against pathogenic infections via innate and adaptive 
mechanisms for immediate defense and long-lasting protection. Innate immune cells, such as 
macrophages, dendritic cells (DCs), natural killer (NK) cells, etc., provide the initial, “first line” of 
protection by recognizing conserved pathogen-associated molecular patterns (PAMPs) via 
pattern-recognition receptors (PRRs) [2], including C-type lectin receptors (CLRs), Toll-like 
receptors (TLRs), nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), 
retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs) and cytosolic DNA sensors [3, 4]. 
Adaptive immunity usually proceeds the innate immune response and requires activation of T 
and B lymphocytes. This activation requires recognition of specific antigens by T and B cell 
receptors and, subsequently results in the generation of antigen-specific effector T cells and/or 
antibody secreting plasma cells. Importantly, adaptive immunity also features production of 
‘memory’ T and B cells that exist in a state of readiness to mount a more rapid attack upon the 
second encounter of a pathogen. Effective activation of adaptive immunity depends on the sensing 
of microbes by PRRs expressed on antigen-presenting cells (APCs) in particular DCs [5]. 
1.1.2 Cross talk between tumor cells and immune system  
Growing evidence has shown that the immune system interacts with tumors throughout tumor 
development, including initiation, progression, invasion, and metastasis. It is also becoming  
 
*With Sections Reprinted from [1] ‘Journal of Controlled Release’, 219 /December 10, Kapadia CH, Perry 
JL, Tian S, Luft JC, DeSimone JM, ‘Nanoparticulate Immunotherapy for cancer’, 167-180, Copyright 
(2015), with permission from Elsevier. 
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Figure-1.1: The three phases of the cancer immunoediting process 
Normal cells (gray) subject to common oncogenic stimuli ultimately undergo transformation and 
become tumor cells (red) (top). Even at early stages of tumorigenesis, these cells may express 
distinct tumor-specific markers and generate proinflammatory “danger” signals that initiate the 
cancer immunoediting process (bottom). In the first phase of elimination, cells and molecules of 
innate and adaptive immunity, which comprise the cancer immunosurveillance network, may 
eradicate the developing tumor and protect the host from tumor formation. However, if this 
process is not successful, the tumor cells may enter the equilibrium phase where they may be 
either maintained chronically or immunologically sculpted by immune “editors” to produce new 
populations of tumor variants. These variants may eventually evade the immune system by a 
variety of mechanisms and become clinically detectable in the escape phase. Figure and caption 
are reprinted from [9] Immunity, Vol 21, Issue 2, Gavin P. Dunn, Lloyd J. Old, Robert D. 
Schreiber; The immunobiology of cancer immunosurveillance and immunoediting. 137-148, 
Copyright (2004), with permission from Elsevier.  
 
clear that the complex cross talk between the immune system and cancer cells can both inhibit 
and enhance tumor growth, which has become a hallmark of cancer [6]. A cancer 
immunoediting model (figure 1.1) [7, 8] has been proposed to explain the paradoxical functions 
of host immunity on cancer, based on the temporal occurrence during tumor progression: an 
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early elimination phase (elimination of tumor cells by a competent immune system), an 
equilibrium phase (a balance phase when tumor progression is still controlled by the immune 
system but sporadic tumor cells that manage to survive immune destruction; immune editing  
occurs) and an escape phase (when the tumor evades immune surveillance and an 
immunosuppressive tumor microenvironment is established). Immune editing is believed to be 
one of the key aspects how tumors evade surveillance and lie dormant in patients for years 
through “equilibrium" and "senescence" before re-emerging [10]. 
1.2. Immune cells and mediators in tumors 
Elimination of cancer cells via the immune system is mainly mediated by immune 
effector cells, such as CD8+ cytotoxic T lymphocytes (CTL), natural killer (NK) cells, and natural 
killer T (NKT) cells. These cells have been found within various types of tumors and studies 
involving cancer patients revealed that the presence of CD3+ or CD8+ tumor-infiltrating 
lymphocytes (TILs) were associated with increased overall survival [11]. CD8+ CTL is the major 
anti-tumor player of adaptive immunity. Recognition and elimination of cancer cells by CD8+ T 
cells requires two signals: 1) a signal provided by the engagement of tumor antigenic 
peptide/class I MHC complex on antigen presenting cells, in particular DCs, with antigen-
specific T cell receptor  (TCR), and 2) stimulatory signals mediated by interactions between 
accessory molecules (CD80, CD86, LFA3) on APCs and their cognate receptors on CTLs (e.g., 
CD2, CD28, LFA1) [12]. Activated CD8+ CTLs kill tumor cells by releasing cytotoxic proteins 
(perforin, granzymes, and granulysin) or engagement of Fas ligand (FasL) on T cells and Fas 
receptor on target cells, and subsequent recruitment of the death-induced signaling complex 
(DISC). NK cells are innate immune effector cells that recognize neoplastic cells via non-
antigen-specific surface receptors [13] and trigger targeted attack through release of cytotoxic 
granules and secretion of cytokines and chemokines to promote subsequent adaptive immune 
responses [14]. NKT cells (also invariant NKT or iNKT cell), another member of innate immune 
system, express a semi-invariant TCR that recognizes lipid antigens (e.g. α-GalCer) presented by 
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CD1d (antigen presenting molecules) [15]. Upon activation, NKT cells rapidly elevate production 
of IFN-, which can profoundly modulate innate and adaptive arms of the immune system for 
tumor rejection.  NKT cells may also directly mediate tumor lysis via Fas-FasL engagement or 
release of perforin [16]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure- 1.2: Immunosuppressive regulators in tumor microenvironment.  
Tumors escape immune surveillance by various mechanisms that operate in parallel with anti-
tumor immunity. Anti-tumor immunity can be suppressed by various cell types including tumor 
cells, stromal cells and immune cells such as MDSCs, Tregs and TAMs. These 
immunosuppressive cells secrete numerous soluble mediators such as arginase, prostaglandin E2, 
TGF-β, IDO, adenosine and NOS2. Arginase and IDO limit T-cell functions by depleting 
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arginine and consuming tryptophan. TGF-β, IDO and IL-10 suppress the activity of T cells and 
natural killer cells as well as cause the expansion of Tregs. TGF-β can also suppress or alter 
activation, maturation and differentiation of DCs, CD4+ and CD8+ T cells. Moreover, due to 
changes in epigenetic machinery of tumor cells, expression of MHC-I/II molecules, proteins 
associated with APM and costimulatory molecules (CD80/CD86) is down-regulated which 
prevents successful antigen presentation and tumor detection. Moreover, tumor cells also express 
surface molecules such as PD-L1/PD-L2 that engage PD-1 receptor on the surface of activated T 
cell which cause the anergy and exhaustion of T cells. CTLA-4 receptor on tumor binds to co-
stimulatory molecules on APCs and prevent antigen presentation. Collectively, tumors escape 
immune surveillance via inhibitory mechanisms utilized by all of these cell types.  
Reprinted from [1] ‘Journal of Controlled Release’, 219 /December 10, Kapadia CH, Perry JL, 
Tian S, Luft JC, DeSimone JM, ‘Nanoparticulate Immunotherapy for cancer’, 167-180, 
Copyright (2015), with permission from Elsevier. 
 
In contrast to immune effector cells, CD25+ regulatory T cells (Tregs) and myeloid 
derived suppressor cells (CD14+ HLA-DR- MDSCs) limit inflammation and immune activation 
[17] and help to maintain self-tolerance (Figure 1.2) [18]. Tregs have been found at high 
frequencies in various neoplastic malignancies such as breast, lung, liver, GI tumors, and 
melanoma contributing to an immune-suppressive tumor microenvironment (TME) [19, 20]. 
Increased recruitment of Tregs is correlated with reduced survival and increased progression in 
pancreatic and ovarian carcinomas [21, 22]. MDSCs also down-regulate both innate and 
adaptive arms of the immune system via a variety of mechanisms, including release of IL-10, 
activation of Tregs, and sequestration of cysteine needed for T cell protein synthesis and 
suppress CD8+ T cell function [23]. Analogous to associations between Tregs and outcome, 
elevated circulating MDSCs correlate with poor prognosis in pancreatic, esophageal, and gastric 
cancers [24].  
Macrophages are divided into two categories based on their functions: classical M1 and 
alternative M2 macrophages. The M1 macrophage is involved in the inflammatory response, 
pathogen clearance, and antitumor immunity while M2 macrophages influence an anti-
inflammatory response, wound healing, and pro-tumorigenic properties. During tumor 
progression, large numbers of monocytes are recruited to the tumor site which then differentiate 
into tumor-associated macrophages (TAMs) [25]. In response to various signals generated from  
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tumor and stromal cells, TAMs are predominantly polarized toward a M2-like phenotype and 
subsequently promote tumor growth, angiogenesis, invasion, and metastasis. Clinical studies 
have suggested that TAM accumulation in tumors correlates with a poor clinical outcome [26] 
In addition to immune cells, immune mediator molecules are also an important part of 
immunoediting process (Figure 1.2). Cytokines such as interferons (IFN), specifically IFN- and 
IFN-α, as well as interleukins (IL) (IL-2, IL-12), and granulocyte macrophage colony-
stimulating factor (GM-CSF) etc., have shown anti-tumor capability and act directly on tumors 
or enhance functions of effector cells. For example, IFN- is one of the major anti-cancer 
immune mediators and is produced by activated Th1 cells (a subset of CD4+ T-helper cells), 
CD8+ T cells, NK cells and NKT cells. IFN- is a potent activator of macrophages, NK cells, 
neutrophil phagocytic activity, and promotes synthesis of Class I and II MHC molecules that 
enhance antigen presentation [27]. Genetic deficiencies in IFN- (or of its receptor) result in 
spontaneous tumor development implying that IFN- plays a crucial role in immunosurveillance 
and elimination of neoplastic cells [28]. On the other hand, a range of inflammation mediators 
[cytokines, chemokines, free radicals, prostaglandins, transcription factors, microRNAs, and 
enzymes such as, arginase (ARG1), indoleamine 2,3-dioxygenase (IDO), cyclooxygenase and 
matrix metalloproteinase (MMP), nitric oxide synthase (NOS2)] are released by or reside in 
cancer cells and immune cells, collectively act to create a favorable microenvironment for the 
development of tumors. Transforming growth factor β (TGF-β) and IL-10 are the major immune 
suppressive cytokines secreted by tumor cells, MDSC, and TAMs while several proinflammatory 
cytokines (IL-1, IL-6, TNF-α) that mediate chronic inflammation in the tumor, significantly 
contribute to tumorigenesis and progression [29]. 
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Figure- 1.3: Immunotherapeutic strategies for cancer.  
A growing understanding of the complex interplay between tumor cells and immune system have 
provided pharmacological targeting opportunities for cancer immunotherapy. Antigen expression 
and presentation of tumor cells can be increased by delivering drugs that manipulate epigenetic 
machinery (5-Aza, 5AHA, etc.). Tumor antigen specific effector cells can be generated via cell 
based or subunit vaccines targeting DCs and the delivery of cytokines and growth factors. 
Blocking of CTLA-4 or PD-1 pathways via antibodies (Anti CTLA-4 or Anti PD-1) can restore 
T cell exhaustion in TME. Immunosuppression can be reversed by many mechanisms – such as 
depleting MDSCs (via All-trans-retinoic acid (ATRA), PDE-5 inhibitors and nitroaspirin), 
depleting Tregs, and TAMs (via bisphosphonates and legumain vaccine) and inhibiting 
regulatory mediators (via siRNA, antibodies or small molecules inhibitors against TGF-β, IDO, 
PDE-5 and COX-2). Reprinted from [1] ‘Journal of Controlled Release’, 219 /December 10, 
Kapadia CH, Perry JL, Tian S, Luft JC, DeSimone JM, ‘Nanoparticulate Immunotherapy for 
cancer’, Pages No.167-180, Copyright (2015), with permission from Elsevier. 
 
Tumor exploit several immunological processes to escape immune surveillance, such as 
increasing Treg cell functionality, down-regulating expression of tumor-associated antigens, 
antigen processing machinery (APM) and accessory/co-stimulatory molecules through 
epigenetic reprogramming and modifying production of immune suppressive mediators. Our 
growing understanding of the complex interplay between tumor cells and the immune system 
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has provided pharmacological targeting opportunities for cancer immunotherapy (Figure 1.3). 
Depending on the approach, immunotherapy could strike more specifically against the tumor, 
thus lowering the damage to healthy tissue and preventing debilitating side effects that are 
nearly unavoidable with radiation, chemotherapy, and surgery. Activated and tumor-specific 
immune cells can invade areas that are difficult/impossible to access surgically, and the immune 
system may, when appropriately stimulated, target even microscopic disease and disseminated 
metastases. Further, immunotherapy should provide long-lasting benefits while by-passing 
issues with multidrug resistance related to chemotherapy and radiation therapy. Also, 
immunotherapy could more efficiently target cancer cells that are slowly dividing or quiescent -
characteristics associated with cancer stem cells. Finally, memory cells elicited by 
immunotherapy may suppress the re-emergence of cancer. This potential of long-term control 
or even complete eradication of the cancer is possibly the most promising aspect of 
immunotherapy since induced anti-tumor responses have sometimes proven durable over many 
years (at least in a subset of patients). 
1.3. Cancer Vaccine- A type of Immunotherapy 
Vaccines are one of the major revolutions in the history of modern medicine. 
Contributions made by vaccines include the almost complete elimination of polio, the 
eradication of small pox and a decrease by more than 95% of the incidence of diphtheria, 
tetanus, pertussis, measles, mumps and rubella [30]. Harnessing the power of a patient’s own 
immune system to target, fight, and eradicate cancer cells without destroying the healthy cells is 
a highly attractive and innovative approach for cancer management. If the immune system is 
appropriately stimulated by an immunotherapy, activated immune cells can target both 
macroscopic and microscopic disease [1]. Developing a successful cancer vaccine, involves 
activation of CTLs with antigens and adjuvants, as well as modulating the immune-evasive 
tumor microenvironment; both are essential for tailoring anti-tumor immune responses. The 
aim of most cancer vaccines is to activate and stimulate tumor specific CD8+ T cells employing 
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either tumor cell-based vaccines, DCs vaccines, T cell vaccines, or peptide/protein-based 
subunit vaccines [31].  
1.3.1 Types of cancer Vaccines 
1.3.1.1 Cell-Based Vaccines  
1.3.1.1.1. Tumor cell based Vaccines 
 Tumor cell-based vaccines utilize autologous or allogeneic tumor cells modified with 
cytokines, such as GM-CSF, or formulated with adjuvants. In autologous tumor cell vaccines, 
tumor cells are derived from the patient, irradiated and combined with cytokines or adjuvants. 
An advantage of cell-based vaccine is that these cells contain the entire spectrum of mutated and 
overly expressed tumor specific protein antigens and present them to patient’s immune system 
[32]. On the other hand, preparation of this type of vaccine requires sufficient numbers of tumor 
cells which is only possible for certain tumor types and stage which limits its feasibility and 
utility in clinical settings. GVAX (GM-CSF transduced autologous tumor cell vaccine) has been  
extensively studied in pre-clinical and clinical trials to recruits DCs [33]. GVAX stimulated the 
maturation of DCs and when combined with anti-CTL-associated antigen 4 (CTLA-4) antibody 
promoted the rejection of murine melanoma [34, 35]. Enhanced antitumor efficacy was 
observed when FVAX (Flt-3 ligand expressing tumor cell based vaccine) or GVAX was combined 
with anti-CTLA-4 or anti-PD-1 antibody in melanoma or ovarian cancer mouse model [36, 37].   
To overcome the limitation of autologous tumor cell vaccine, an allogeneic tumor cell 
vaccine has been developed which includes two or three human tumor cell lines. Allogeneic 
tumor cells can be easily modified to express immunostimulatory cytokines and can be produced 
at a large scale. Canvaxin™ is a combination of three melanoma tumor cell lines, which were 
selected from 150 tumor cell lines on the basis of their tumor antigen profile. Canvaxin™ 
contain 20 different melanoma associated and tumor associated antigens from which at least 
one antigen was found in every melanoma patient studied to date. It has produced striking 
results in clinical studies for stage II and stage IV melanoma [38]. Algenpantucel-L and 
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Tergenpantucel-L are others antigen-expressing whole cell vaccines which are reviewed 
elsewhere [39]. 
1.3.1.1.2. Dendritic cell based Vaccines 
Dendritic cells are professional antigen-presenting cells that play an essential role in 
generating robust antigen-specific T cell immune responses against cancer.  Immunotherapeutic 
strategies have attempted to utilize the ability of dendritic cells to deliver antigens as a means of 
therapeutic vaccination in individuals with advanced malignancies [40-42]. In 1995, the first 
clinical trial was carried out to investigate therapeutic dendritic cell cancer vaccines for the 
treatment of melanoma [40]. For these studies, DCs were generated ex vivo by culturing a 
patient’s own hematopoietic progenitor cells with cytokine combinations, pulsed with tumor 
antigens, followed by ex vivo maturation, and then administered back into the patient to elicit 
an immune response against the cancer cells carrying the antigens. Sipuleucel-T (Provenge) 
was the first DC-based therapeutic cancer vaccine approved in 2010 by the FDA, for the 
treatment of prostate cancer [43]. As a personalized therapy, DC vaccines are highly labor 
intensive, requiring skilled technicians to isolate and expand cells from each patient, a process 
that can take between 4 to 16 weeks, which might not be feasible for patients with highly 
progressive diseases.  Furthermore, storage, transportation, and reconstitution of these cellular 
vaccines are problematic. These issues combined make these cellular vaccines very expensive 
[44]. In addition, even though the vaccination resulted in antigen-specific CTL responses at the 
immunization and metastatic disease sites , no major therapeutic response was demonstrated in 
many advanced tumors [40]. One hypothesis regarding the lack of response was that immune 
inhibitory pathways elicited by the TME prevented CTLs from exerting their functions.  
Therefore, as discussed, inhibiting immune checkpoint receptors CTLA-4 and PD-1 (involved in 
the negative regulation of CTL function) and modulating immunosuppressive environment may 
be good companion therapies for DC vaccines. 
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1.3.1.1.3. T cell based Vaccines  
The isolation, stimulation, and reinfusion of patients’ T lymphocytes for the treatment of 
disease, termed adoptive cell transfer (ACT), was initially reported in the 1980’s. ACT has been 
utilized for the stimulation and expansion of potent antigen-specific T cells that can kill cancer 
cells.  The primary challenges in this field are identifying tumor-specific targets and avoiding 
off-target toxicities. Using this approach a personalized treatment can be achieved based on 
growing tumor-infiltrating lymphocytes (TIL) ex vivo from surgically excised tumor specimens 
of patients and then adoptively transferring them back into the patient [45]. This treatment is 
often coupled with IL-2 therapy and has been used on a number of different cancers – renal cell 
carcinoma, breast cancer, oral squamous cell carcinoma, and non-small cell lung cancer [45, 
46]. A similar therapy utilizes genetically modified T cells, which target cancer through a 
chimeric antigen receptor (CAR). T cells are isolated, modified with T cell signaling domains 
that are fused with antibody derived targeting domains, and then infused back into patients.  
This therapy redirects the effector function of T cells towards specific tumor associated antigens 
(TAAs), without the requirement of antigen processing or presentation. CAR T cell therapy has 
been successful in treating patients with hematologic malignancies, however it has been less 
effective in treating solid tumors [47]. Although these therapies have great potential to be 
efficacious – it is extremely difficult to offer as a widely available therapy since the cell culture 
process requires extensive manipulation by highly skilled scientists/technicians.    
1.3.1.2. Genetic Vaccine 
 Delivering antigen fragments via viral vectors or plasmid DNA is another method to 
transfect locally infiltrated APCs in muscles or skin. One major advantage of genetic vaccines is 
to delivery of multiple antigens in one immunization to stimulate different arms of immunity. 
Plasmid DNA or viral vectors are shuttle system to deliver them to target cells and to express 
antigenic proteins. The backbone of bacterial DNA itself acts as a PAMPs and stimulate innate 
arm of immune system by activating TLRs or other PRRs [48]. Moreover, DNA vaccine can be 
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combined with TLR agonists. HER-2/neu targeted or CEA targeted DNA vaccine when delivered 
(via electroporation) with TLR9 agonist IMO (immunomodulatory oligonucleotide) or with 
TLR7 agonist SM360320 resulted into inhibition of tumor growth in HER-2 positive mammary 
carcinoma and CEA positive colon carcinoma transgenic mouse model [49, 50]. Furthermore, 
fusion of CD4+ antigenic fragments with CD8+ antigenic fragments can be easily done to 
generate helper CD4+ T cells to boost CD8+ T cells response and to create long lasting memory 
[51]. Viral vectors with less disease causing potential and low intrinsic immunogenicity can be 
engineered to encode TAA or TAA with immunostimulating molecules. One of such vaccine 
platform called PROSTVAC is a replication incompetent vaccinia virus vector consist of  a 
construct for prostate specific antigen (PSA) and three immunostimulatory molecules CD80, 
CD54 and CD58. PROSTVAC® has improved median overall survival (OS) to the control (25.5 
months vs 16.1 months) when tested in double-blinded phase II clinical study for castration-
resistant prostate cancer [52]. TG4010, ProstAtakTM, -V/F-TRICOM™ and Alvax are other viral 
vector based vaccines which have been reviewed in details elsewhere [39]. Although DNA 
vaccination platform achieved significant success in mouse and rat models, translation into non-
human primates and human remains biggest challenge for this type of vaccine. Perhaps new 
drug delivery platforms need to be designed for the delivery of plasmid DNA to achieve 
maximum transfection efficiency to induce more efficient and potent response in clinical trials.    
1.3.1.3. Protein and Peptide based Vaccine 
 Perhaps, the most common vaccine strategy is to deliver MHC-I (HLA) restricted tumor 
associated antigenic peptides with adjuvants or immunomodulatory cytokines to induce potent 
CTLs response against tumors.  In contrast to cellular vaccines, specific components of subunit 
vaccines (viral or non-viral-based recombinant antigen proteins, antigenic peptides, formulated 
with or without adjuvants such as TLR agonists) can be directly administered to the patient, to 
induce high numbers of antigen-specific effector and memory T cells. These vaccines rely on the 
patients’ endogenous DCs for their uptake and antigen presentation. Components of subunit 
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vaccines can be readily designed based on recombinant technology and epitope focusing and 
these vaccines can be easily stored and transported. Peptide based vaccines for cancer have been 
in clinical trials since 1995 [39, 53]. There have been durable clinical responses in some patients 
that receive melanoma vaccines, however overall positive clinical response rates were low.  In an 
effort to improve subunit vaccines, researchers have moved away from using short peptides 
(which have little or no tertiary structure and thus undergo rapid degradation in tissue and 
serum) to longer peptides [39, 53]. These longer peptides prevent degradation by exopeptidase 
and provide extra “handles” to proteasome and APM to present with MHC-I. Additionally the 
longer peptides have the potential to induce memory CD8+ T cells. Currently there are several 
Phase III clinical trials of subunit cancer vaccines with multiple tumor types, such as peptide-
based gp100, IMA901, NeuVax, etc., have been reviewed in detail elsewhere [54]. 
1.4. Challenges in the development of Cancer Vaccines  
As discussed earlier: i) APCs carry the antigen from vaccines, travel to the nearest lymph 
nodes and cross-present these tumor associated antigens on their surface MHC proteins, ii) in 
lymph nodes, naïve T cells recognize these antigens via binding of surface TCR to MHC-I/p 
complexes and in presence of other co-stimulatory signals they proliferate, and iii) as T cells 
increase in numbers they identify tumor cells, perform their effector functions at tumor site and 
prevent the spread of tumor by killing tumor cells. All three steps are very critical and important 
for effectiveness of cancer vaccine to generate potent immune response against tumor.  
 Inducing high numbers of functional CD8+ T cells against tumor antigens is not a trivial 
task.  Once T cells proliferate, antigen recognition on tumor cells happens in the periphery-away 
from lymph nodes. CD8+ T cells can recognize antigens on tumor cells as a ‘foreign’ and 
proliferate or CD8+ T cells can undergo anergy and deactivation if antigens are recognized as a 
‘self’. Since tumor antigens are already present in the body, most of them can be recognized as a 
self-antigens resulting in T cell anergy and deactivation. On the contrary, due to ongoing 
antitumor immune response in the body, these antigen carrying APCs may be recognized as a 
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‘tumor’ and can be eliminated by CD8+ T cells. If high numbers of CTLs are generated against 
tumor cells, lack of pro-inflammatory cytokines in tumor microenvironment and presence of 
immunosuppressive regulators can prevent them from performing their effector functions 
therefore rendering therapeutic vaccination ineffective.  
Generally, during bacterial or viral infections, infected cells secrete chemokines and 
cytokines which attract effector cells to the site of infection. Due to immunosuppressive 
microenvironment tumor downregulates chemokines which attract effector immune cells. 
Moreover, immunosuppressive cellular and soluble mediators prevent T cells from carrying out 
their effector functions resulting in suppression of anti-tumor immune responses.  Therefore, 
induction of high numbers of potent effective CTLs and modulating the immunosuppressive 
tumor microenvironment are crucial steps for the success of cancer vaccine. Engineering a 
particulate carrier system to deliver tumor antigens in order to achieve maximum immune 
response are discussed in chapter-2.   
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Chapter-2: Delivery of Cancer Vaccine using Nanoparticles* 
2.1. Introduction 
The key advantages of using nanoparticulate carriers are improved solubility and 
bioavailability of the cargo.  They can be loaded with a variety of cargos such as siRNA, peptides, 
proteins, and small molecule therapeutics. Importantly, by associating the cargo with a 
nanoparticulate carrier, the cargo can be protected from degradation, which can increase its half-
life, enhancing potential efficacy.  Furthermore, these systems can be modified for targeted site-
specific delivery, mitigating systemic toxicity issues. To date, there are 45 nanoparticulate 
formulations approved for clinical use including liposomes for cancer therapeutics and diagnostic 
agents, polymer-protein conjugates of IFN-α, GM-CSF and anti-TNF-α monocloncal antibodies 
for tumor therapy, and virosomes for flu vaccines [2].  
There are a multitude of methods for fabricating nanoparticles (NPs) – varying from 
formation of micelles [3], liposomes [4], emulsions [5], or through a template/particle molding 
techniques [6, 7]. Using these techniques, NPs can be composed of an assortment of different 
materials, with varying sizes, shapes, and chemical and surface properties. Possessing the 
manufacturing platforms to control and design nanoparticles possessing specific parameters 
allows investigators the unique ability to match optimized NPs to the specific delivery 
requirements. For example, the design parameters for the delivery of immunotherapy agents that 
require systemic (intravenous) delivery and accumulation and release at the tumor site, will differ 
from those that require local delivery to tissue resident APC’s or to draining lymph nodes. Design 
parameters for delivery of subunit vaccine are outlined below.  
*With Sections Reprinted from [1] ‘Journal of Controlled Release’, 219 /December 10, Kapadia CH, Perry 
JL, Tian S, Luft JC, DeSimone JM, ‘Nanoparticulate Immunotherapy for cancer’, 167-180, Copyright 
(2015), with permission from Elsevier. 
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2.2. Particle design parameters for local delivery to immune cells 
The development of nanoparticles to target immune cells is a newer field, however much 
work has gone into designing particles to deliver cargo to tissue resident APC’s or drain and 
trigger activation of immune cells residing in lymph node, as required for vaccine 
administrations. For these applications particles are administered subcutaneously, 
intradermally, intramuscularly, intraperitoneally, etc. Since the adaptive immune response is 
mainly initiated in secondary lymphoid organs, transport of nanoparticulate vaccine to the 
draining lymph node (dLN) is an important factor in designing these nanocarriers. As shown in 
figure-2.1, the size of nanoparticulate carrier plays an important role in shaping an immune 
response; it not only influences cellular uptake and intracellular trafficking, but also affects 
lymphatic trafficking. NPs from 5 nm to 100 nm in size, transport via convective force and 
diffuse deeper into the extracellular matrix and are able to travel to dLNs by afferent lymphatic 
vesicles. Particles greater than 500 nm remains trapped in extracellular matrixes [8]. These 
larger particles can potentially be taken up by resident APCs and then trafficked to the dLNs [9]. 
Once they reach the dLNs, retention of NPs is also dependent on their size. Larger particles will 
be taken up by subcapsular macrophages whereas smaller particles can directly access T cell 
region and can be taken up by immature DCs residing within LNs [8]. Moreover, in the dLNs, 
smaller nanoparticles can target larger numbers of immature DCs, B cells and T cells [10]. 
Reddy et al. have shown higher lymphatic drainage and lymph node retention of 20 nm and 45 
nm polypropylene disulfide (PPS) NPs as compared to 100 nm NPs after intradermal injections. 
Retention of smaller sized particles was seen up to 5 days [11]. Mueller et al., have also shown 
the importance of particle size for targeting LNs and generating a better humoral response. In 
comparing non-draining 1 ×1 μm cylindrical particles, to rapidly draining 80 × 180 nm rod-
shaped particles, smaller particles were able to sustain prolonged antigen presentation to APCs 
and elicited a stronger humoral response than the non-draining 1 × 1 μm NPs [12]. Furthermore, 
Fifis et al. also demonstrated the significance of size in generating anti-tumor immune response 
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utilizing 40 nm and 100 nm ovalbumin coated particles. The 40 nm particles were able to drain 
to LNs and localized with residing DCs to a higher extent than 100 nm particles, and were able 
to induce prophylactic as well therapeutic immunization responses against the tumor. These 
studies indicate that targeting immature DCs residing LNs is a successful strategy to elicit 
antigen specific immune response [13]. This concept is further supported by positive results  
 
 
Figure-2.1: Effects of particulate size on tissue, cell and intracellular targets after entry 
into interstitial tissue. 
a, After injection into the interstitium (that is, intramuscular, intradermal or subcutaneous 
injection, for instance), particles (whose definition here includes molecules) will disperse and 
convect with interstitial flow, driven by transient pressure gradients that arise from the injection 
as well as the natural small pressure gradient between blood and lymphatic capillaries. Very 
small particles (red), whose diffusion velocity is greater than convective velocity, can readily 
diffuse and will rapidly dilute in local concentration, which limits the effective lymphatic 
concentration. Larger, intermediate-sized (blue) particles have smaller diffusion speeds and 
furthermore are transported within the more permeable regions of the extracellular matrix (as in 
size-exclusion chromatography). Their transport is thus governed more by convection, and they 
are more efficiently directed into the lymphatic vessels. As size increases, however, steric 
hindrance becomes limiting, and particles that are too large (over about 500 nm, although this 
depends on tissue, level of hydration and experimental conditions) remain mostly trapped in the 
interstitial space. b, Once inside the lymphatic vessel, lymph node (LN) retention positively 
correlates with particle size. Larger (or opsonized) particles are readily taken up by subcapsular 
macrophages, whereas intermediate-sized particles can directly access the T-cell zone and 
associated dendritic cells. The B-cell zone conduits, however, which are formed by follicular 
dendritic cells (FDC), restrict access to particles under about 3 nm. Figure and caption are 
reprinted by permission from Macmillan Publishers Ltd: [NATURE MATERIALS] [8], 
copyright (2013).  
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from human clinical trials utilizing 40 nm ISOMATRIX particle which induced potent CD8+ T 
cell [14]. 
Particle surface charge can also affect lymphatic drainage and lymphatic retention. The 
extracellular matrix (ECM) is made up of collagen fibers and negatively charged proteins 
(glycosaminoglycans), therefore positively charged (cationic) particles remain trapped at the 
injection site and possibly phagocytosed by APCs and then trafficked to the LNs [15]. In 
contrast, particles that are negatively charged and neutral/surface pacified with PEG have 
limited interaction with the ECM, which facilitate their traffic to dLN either through enhanced 
trafficking in lymphatic vesicles or through internalization by migratory DCs [16]. Furthermore, 
surface ligand coatings are highly important in determining the outcome of particles. APCs and 
B cells are able to recognize pathogens by their surfaces, which are densely covered with 
proteins, lipids and polysaccharides. By mimicking these highly repetitive patterns (HRP) of 
biomolecules on the surface of particulate carriers, we can enhance multivalent antigen 
presentation and induce more a robust and potent immune response. In multivalent ligand 
vaccines, increasing the valency of ligands on NPs increases avidity and apparent binding, which 
influences cell surface receptor clustering for signal transduction [15]. More specifically, 15-20 
hapten molecules that are spaced 5-10 nm apart (similar to the average spacing of viral coat 
proteins) is an ideal special arrangement to efficiently activate B cell receptors [17]. Highly 
repetitive patterns of antigen/adjuvants on nanoparticulate carriers allow efficient binding of 
natural IgM antibodies through high-avidity interactions, leading to recruitment and activation 
of complement component 1q (C1q) and the classical pathway of the complement cascade [17]. 
Furthermore, hydrophilic nanoparticle surfaces such as polyhydroxylated (-OH) pluronic-coated 
NPs, can activate alternative pathways of complement activation [18]. Therefore changing 
chemical groups on particle surface (by changing chemistry of polymer or linkers) may allow us 
to manipulate their capacity to trigger the complement activation cascade and opsonization 
profile [19].  
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2.3. Delivery of subunit vaccine via particulate carriers 
Subunit vaccines offer a safer and more specific approach to generate immunity, by 
administering specific components of pathogenic organisms (e.g. bacterial coat proteins, 
peptides, carbohydrates or lipids) to stimulate the immune system. In the soluble form these 
biomolecules suffer from poor immunogenicity as well as short in vivo half-lives that limit their 
ability to reach target cells. This necessitates design of nanoparticle carriers to deliver subunit 
vaccines that target APCs and specific cellular compartments. Specifically, cytosolic delivery of 
exogenous antigen into MHC class I presentation pathway of APCs is required to induce potent 
CTLs response. Lipid–calcium–phosphate (LCP) nanoparticles represent a new class of 
intracellular delivery systems for sending cell membrane impermeable antigens to cytosol to 
induce CTLs response in cancer immunotherapy. Xu et al. have co-encapsulated Trp-2 
(tyrosinase related protein-2, melanoma associated antigen) peptide and CpG ODN in mannose 
decorated LCP nanoparticles which resulted in higher cargo deposition to LNs and superior 
inhibition of tumor growth in both B16F10 melanoma subcutaneous and lung metastasis models 
[20]. Interestingly, Vasievich et al. reported that a cancer vaccine with Trp-2 peptide and a 
cationic lipid (R)-DOTAP (1, 2-dioleoyl-3-trimethylammonium-propane) formulated into 
nanocomplexes was able to elicit high population of functionally active tumor-infiltrating 
lymphocytes and break the T cell tolerance in tumor in a murine melanoma model, achieving 
significantly delayed tumor growth [21]. 
Since cancerous cells can escape immune surveillance via multiple mechanisms, utilizing 
a single epitope peptide restricted to MHC-I might not be sufficient to generate efficient anti-
tumor immune response. Nanoparticulate delivery systems offer the opportunity to deliver 
multiple epitope peptide vaccines to a single cell. Tan et al., have shown that combinational 
delivery of multiple NPs carrying different tumor-associated antigen (TAA) peptides generated a 
better anti-tumor response than NPs loaded with single peptide epitope. Specifically, delivery of 
PLGA emulsion carrying TAA peptides Trp-2, gp100, and immunosuppressive retroviral protein 
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epitope p15E had significantly better tumor regression and survival in B16F10 murine 
melanoma model as compared to PLGA emulsion loaded with only a single TAA peptide [22].  
Moreover, particulate carriers can provide sustained release of antigens to induce more 
potent cellular responses and immune memory. PLGA is a commonly used biodegradable 
polymer in nanoparticle synthesis, with physicochemical properties readily tunable to achieve 
various degradation profiles and cargo release kinetics. Liposomes are another commonly used 
particulate carrier, in which cargo release is achieved after disruption of lipid bi-layer. In 
comparing release kinetics, liposomes typically release their cargo at a faster rate than the PLGA 
nanoparticles. In comparing these release kinetics, it was found that a prolonged and sustained 
release from PLGA NPs resulted in persistent antibody titers, stronger cellular responses and 
higher frequency of effector T cells as compare to liposomal formulation [23].  
2.4. Targeting DCs via nanoparticulate vaccine  
Dendritic cells are the major class of APCs. Targeting DCs via antibodies against their 
cell surface receptor such as DC205, CD40 or CD11c, for delivery of subunit vaccine components 
can increase the efficiency of cross-presentation and induce more potent CD8+ T cells.  Cruz et 
al. have evaluated the efficiency of these different targeting strategies to activate DCs and elicit a 
potent CD8+ T cell response. Model antigen protein ovalbumin (OVA), TLR3 ligand Poly I:C and 
TLR7/8 ligand R848 were encapsulated in PLGA NPs decorated with different antibodies 
against surface receptors, DEC205, CD11c, and CD40. All targeted NPs stimulated in vitro DCs 
for expression of co-stimulatory molecules and production of IL-12, and induced proliferation of 
antigen specific IFN-γ producing CD8+ T cells. Subcutaneous vaccination of CD40, DEC205 and 
CD11c targeted NPs in C57BL/6 mice induced significantly higher frequency of CTLs as compare 
to non-targeted NPs [24]. In another study, Rosalia et al. have improved the delivery of OVA 
protein to DCs and induced potent anti-tumor immune response in B16-OVA melanoma model 
in mice via co-delivery of OVA, Pam3CSK4 (TLR3 agonist) and poly I:C (TLR3 agonist) in anti-
CD40 Ab decorated PLGA NPs [25].     
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DCs can also up-regulate co-inhibitory molecules including PD-L1 and PD-L2. The 
balance in expression level and activation of co-stimulatory molecules and inhibitory molecules 
determines the activation state of T cells. Hobo et al. have achieved efficient knockdown of PD-L 
expression on human monocyte derived DC and superior induction of ex vivo antigen-specific T 
cells via intracellular delivery of PD-L1 and PD-L2 siRNA using cationic lipid nanoparticles 
(LNP) and delivery of antigen peptide mRNA via electroporation [26]. Moreover, similar groups 
have also developed DOPE based NPs to delivery PD-L1 and PD-L2 siRNA which increased 
transfection efficiency and suppression of PD-L1 and PD-L2 [27]. In another study, Cubillos-
Ruiz et al. has shown increased uptake of NPs to tumor associated regulatory DCs via delivery of 
siRNA- PEI nanocomplexes [114]. Delivery of siRNA via PEI complexes converted regulatory 
DCs to antigen presenting DCs and also enhanced tumoricidal activity of DCs via TLR5 
stimulation. Moreover, siRNA delivery via PEI complexes significantly reduced tumor growth 
and improved survival of ovarian carcinoma bearing mice [28]. Similarly, Teo et al., have 
increased siRNA uptake and reduced toxicity of NPs, when PD-L1 siRNA was delivered to PD-L1 
overexpressed epithelial ovarian cells via PEI-PEG-siRNA complexes. Delivery of PD-L1 siRNA 
via PEI nanocomplexes resulted into 40% to 50% of PD-L1 knockdown with two fold increased 
sensitivity of SKOV-3 to T cell killing as compare to scrambled siRNA sequence [29].  
2.5. PRINT (Particle Replication in Non-wetting Template) - a platform for delivery 
of subunit vaccine 
 PRINT (Particle Replication in Non-Wetting Template) is a unique nanofabrication 
technique which combines modern soft-lithographic principles from microelectronic industries 
with the flexible molding properties of PFPE (perfluoropolyether) to produce nano-
microparticles with unprecedented control of size and shape. It has been found and developed in 
the lab of DeSimone at UNC Chapel Hill and its spin out company Liquidia Technologies Inc. 
which has developed cGMP compliant PRINT plant for its use in phase I clinical trial [30, 31].  
Similar to other soft lithographic techniques PRINT involves fabrication of PFPE molds from 
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master templates, following by filling the mold with a pre-particle solution, solidifying the 
particles in the mold, then transferring the particles out of the mold and onto a water soluble 
polymer sheet [31]. PRINT fabrication process is shown in following figure-2.2.  
 
 
Figure-2.2: PRINT®- fabrication process. 
PRINT fabrication process begins with applying pre-particle (precursor) organic solution of 
polymer or monomer or proteins (red) to a polyethylene terephthalate (PET) delivery sheet 
(gray) by mayer rod. Then PFPE mold (green) is laminated against the thin layer of pre-particle 
sheet and passed through a heated nip (gray). The mold cavities are filled with a material of 
choice. Filled mold is laminated against water soluble polymer sheet (yellow) such as PVA or 
Plasdone™ and passed through a heated nip. Particles (red dots) are transferred onto harvesting 
layer sheet. Very monodispersed particles are collected by dissolving sacrificial harvesting layer 
of water soluble polymer into water.  
 
PRINT begins with the etching the micro-nano cavities of precise size and shape on 
silicon wafer. Molds are manufactured by applying photocurable elastomeric PFPE to the silicon 
master template. The low surface energy of PFPE enables complete wetting of the silicone 
master template which allows patterning of consistently high density features from 10 nm to 1 
µm. The pre-particle solutions (combinations of polymers, monomers, proteins, nucleic acids, 
therapeutic drugs) fill all cavities in the mold by capillary action and/or mechanical forces. 
Moreover, low surface energy prevents the wetting of the land area between the cavities of mold 
allowing the production of highly monodisperse nano/micro particles without an interconnected 
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flash layer [31]. After filling the mold, particles can be removed by transferring them to 
harvesting sheet composed of water soluble polymers. Common harvesting materials used are 
poly (vinyl) alcohol (PVA) and Plasdone™. Transferred particles are collected via dissolving the 
sacrificial harvesting layers in water yielding empty molds and nearly mono-disperse particles. 
Monodisperse particle can be lyophilized or store for future chemical modification.  
The versatility of PRINT technologies allows investigators to fill the mold with different 
materials such as PLGA, photo curable cross-linked acrylate monomers, proteins, and 
chemotherapeutics, providing exquisite control over modulus, composition, and surface 
chemistries [32, 33]. Additionally, fluorescent dyes can be incorporated into appropriate particle 
compositions to study bio-distribution as well as lymphatic trafficking [12]. Special monomers 
can also be incorporated into particle matrix to provide different functional handle for addition 
of surface ligands such as PEG, targeting affibody, or protein antigens [34].  
For subunit vaccine delivery, PRINT technology allows for the fabrication of particles 
that mimic the features of known pathogens (size, shape, and surface composition). Previous 
work has shown that delivery of trivalent influenza antigenic protein adsorbed onto cationic 
PLGA PRINT nanoparticles is safe and produced better antigen-specific antibody responses 
when compared to inactivated virus vaccine [35]. Fromen et al. has shown potent mucosal and 
humoral immune responses in mice when model antigenic protein conjugated to PEG hydrogel 
PRINT particles were delivered through intranasal immunization [36]. Moreover, Mueller et al. 
has shown the importance of particle size in production of antibody response. Model ovalbumin 
protein conjugated to 80X180 nm PRINT PEG hydrogel particles were more efficiently taken up 
by key APCs and stimulated helper CD4+ T cell responses to boost humoral immunity as 
compared to 1 µm sized PRINT PEG hydrogel particles [12]. Although successful delivery of 
model protein resulted into potent humoral immune response, optimization and development is 
still needed to induce potent cellular immune response to fight against cancer and intracellular 
pathogens. The goal of my dissertation project is to design the delivery system for model as well 
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as tumor antigenic peptides and adjuvants to induce cellular immune response to fight against 
cancer. The next chapter focuses on the design of a PRINT hydrogel particulate platform for the 
delivery of model antigenic peptide-SIINFEKL (MHC-I epitope of Ovalbumin) and CpG ODN by 
utilizing intracellular reduction sensitive environment of APCs.  
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Chapter-3: Reduction Sensitive PEG Hydrogels for Co-delivery of Antigen and 
Adjuvant to Induce Potent CTL* 
3.1. Introduction  
Vaccines are one of the major discoveries in modern medicine. Contributions include the 
almost complete elimination of polio, eradication of small pox, and a decrease by more than 95% 
of the incidence of diseases such as diphtheria, tetanus, pertussis, measles, mumps and rubella 
[1]. Vaccines have substantially decreased morbidity and mortality related to infectious disease 
and increased the average life span in the twenty-first century. Despite these successes, there is 
a clear need to develop vaccines against pathogens like human immunodeficiency virus (HIV), 
hepatitis C virus (HCV), and diseases such as malaria, tuberculosis, and cancer. Although 
effective, traditional vaccines utilize live or attenuated pathogens which pose safety concerns 
due to the administration of unnecessary components of pathogenic micro-organism [2]. 
New-generation subunit vaccines offer a safer and more specific approach to generate 
immunity, in which very specific components of pathogenic organisms (e.g. bacterial coat 
proteins, peptides, carbohydrates or lipids; immunogenic determinants) are administered to 
protect against disease. Clinical success of subunit vaccines include the use of Fluvirin® 
(trivalent subunit protein) and Influvac (inactivated purified surface antigens from influenza 
virus) against influenza, BioThrax® (AVA-anthrax adsorbed vaccine, contains no whole cell or 
live bacteria) against anthrax, Cervarix® (contains a mixture of human papilloma virus protein 
antigens with adjuvants alum and monophosphoryl lipid-A) against cervical cancer caused by 
HPV [3]. Because of our improved understanding of the immune system, more specific and safer  
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peptide epitopes are being designed based on recombinant technology and epitope focusing [4].  
Peptide antigens are easily synthesized, stored and transported. Specific antigenic 
peptide epitopes can induce an antigen specific cytotoxic T cell (CTL) response, which is of the 
utmost importance in the elimination of intracellular pathogens, as well as cancer cells. 
Successful intracellular delivery of peptides to professional APCs (mostly dendritic cells [DCs]) 
and their cross-presentation to T cells elicit CTLs. For cross-presentation, APCs can process 
endocytosed antigens by either the classical (also cytosolic pathway) or vacuolar pathway. In the 
classical pathway, protein antigens are processed into 8 to 12 amino acids fragments by 
proteasomal degradation machinery in cytosol and loaded onto MHC-I molecules in the 
endoplasmic reticulum (ER) or phagosome by antigen processing machinery (APM). In the 
vacuolar pathway, degradation of pathogens/antigens and loading of peptide fragments to 
MHC-I occurs in the endosome [5]. However, soluble peptides suffer from fast degradation half-
life (from a few seconds to minutes depending on their length) [6] and low cellular uptake, 
resulting in poor cross-presentation by DCs and lower immunogenicity.  
Many particulate subunit vaccine delivery systems such as liposomes, nano-beads, solid-
lipid nanoparticles, polymeric nanoparticle and micelles, etc. have been investigated as a 
delivery vehicle to induce protection against HIV, influenza and cancer [7]. Particulate carrier 
systems can improve immunogenicity of antigens and adjuvants by mimicking the size, shape 
and/or surface molecule organization of pathogens, in order to facilitate uptake by APCs [8]. 
Additionally they prevent enzymatic degradation of antigens/adjuvants, and facilitate their 
intracellular delivery by increasing their local resident time [9]. Depending on their degradation 
mechanism, the antigen can be released into the late endosome/ lysosome or into cytosol. By 
optimizing the polymeric material of the nanoparticulate carrier, release of antigen can be 
triggered by changes in an intracellular pH [10, 11], slower degradation rate of biodegradable 
polymeric carrier [12-14], or enzyme mediated release of antigen such as endo-lysosomal lipases 
[15] or α-chymotrypsin [16]. 
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Efficient activation of DCs as well as induction and proliferation of T cells also requires 
co-stimulatory signals which can be provided by delivering adjuvants [17]. Co-delivery of 
antigens with adjuvants using particulate carriers can further boost the immune response [18, 
19]. Many immune stimulating agents such as alum, oil in water emulsions, various TLR/NLR 
agonists etc. are being explored in clinical, as well as pre-clinical studies as vaccine adjuvants 
[20]. TLR agonists such as MPL-A, CpG, resiquimod, poly I:C etc. have been investigated in the 
development of particulate vaccines [4]. Antigen and adjuvant can be encapsulated, adsorbed, 
or conjugated to NPs. Sarti el al. demonstrated induction of IgA titers via co-delivery of 
encapsulated mono-phosphoryl lipid-A (MPL-A) and ovalbumin (ova) through PLGA particles 
[21]. Particle conjugated CpG and ova have induced CD8+ effector as well as memory T cells in 
mice [22]. 
In this study, we have designed a PRINT® NP sub-unit vaccine to deliver a MHC-I 
epitope (SIINFEKL) of ovalbumin and a TLR-9 agonist, CpG oligonucleotide (ODN). PRINT 
offers the ability to mold biocompatible nanoparticles with complete control over particle size, 
shape and chemical composition in a manner heretofore not possible with other particle 
technologies. High aspect ratio (80 × 80 × 320 nm, aspect ratio = 4) particles were chosen since 
the rod-shape emulates known pathogens [23] and increased aspect ratio is known to  enhance 
cellular uptake [24]. The antigenic peptide (CSIINFEKL) and adjuvant (CpG ODN) were surface 
conjugated to NPs through reduction sensitive linkers, taking of the intracellular reducing 
environment to trigger their release. Two cleavable linkers were investigated, a short SPDP 
(succinimidyl 3-(2-pyridyldithio) propionate linker, and long NHS-PEG(2k)-OPSS linker. SPDP 
has been widely used to conjugate amine groups to thiol groups for intracellular delivery of 
siRNA-polymer conjugates [25, 26], aptamer toxins, aptamer virus capsid conjugates [27, 28], 
delivery of siRNA or DNA NPs [29-32], or delivery of model antigen ovalbumin via NPs [33-35]. 
Though, the NHS-PEG-OPSS linker has not been used as extensively in the literature, there is 
much evidence to the support the hypothesis that linker length is important.  For example, Chen 
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et al showed higher immunostimulatory response gold labeled CpG ODN by increasing the 
proximity of CpG ODN to gold nanoparticles [36]. Furthermore, Singh et al was able to 
demonstrate the effect of linker length on gene silencing efficiency of siRNA conjugated to 
quantum dots [37]. We therefore hypothesized that linker length would play a significant role in 
the accessibility of bio-molecules to their appropriate receptors. Our work demonstrates the 
significant role that linker length plays in the development of particulate based sub-unit 
vaccines.  Herein we report the formulation of highly uniform and monodisperse hydrogel 
PRINT NPs co-conjugated with SIINFEKL and CpG, that are successfully taken up and 
processed by BMDCs, resulting in their efficient maturation and leading to SIINFEKL cross-
presentation and subsequent induction of potent antigen-specific T cell proliferation and 
cytotoxic activity. 
3.2. Materials and Methods 
3.2.1. Materials 
Poly (ethylene glycol) diacrylate (Mn 700) (PEG700DA), 2-aminoethyl methacrylate 
hydrochloride (AEM), diphenyl (2, 4, 6-trimethylbenzoyl)-phosphine oxide (TPO), thiol 
modified CpG 1826 (C6-S-S-C6-tccatgacgttcctgacgtt), dithiothreitol (DTT), sucrose and DNAse, 
RNAse free sterile water were purchased from Sigma-Aldrich. Tetraethylene glycol 
monoacrylate (HP4A) was synthesized in house. Cysteine modified OVA257-264 (CSIINFEKL) 
were purchased from Peptide 2.0. Trifluoroacetic acid, methanol, dimethyl sulfoxide (DMSO), 
PTFE (polytetrafluoroethylene) syringe filters (13-mm membrane, 0.22-μm pore size), HPLC 
grade water and acetonitrile were obtained from Fisher Scientific. Conventional filters (2-μm) 
were purchased from Agilent Technologies, and polyvinyl alcohol (Mw 2000) (PVOH) was 
purchased from Acros Organics. (N-Succinimidyl 3-(2-pyridyldithio)-propionate (SPDP) was 
purchased from Thermo Scientific. Ortho-Pyridyldisulfide-PEG-N-Hydroxylsuccinimide ester 
(NHS-PEG (2k)-OPSS) was purchased from Creative PEGworks. PRINT molds (80 nm × 320 
nm) were obtained from Liquidia Technologies. DNA grade NAP-10 columns were purchased 
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from GE Healthcare. RPMI1640 medium, penicillin and streptomycin, L-glutamine, fetal bovine 
serum (FBS) were all from Life Technologies.  
3.2.2. Methods 
3.2.2.1. PRINT nanoparticle fabrication 
The PRINT particle fabrication process is described previously [38]. Briefly, the pre-particle 
solution was prepared by dissolving 3.5 weight percent (wt %) of the various reactive monomers 
in isopropyl alcohol (IPA). The reactive monomers included: a cure-site monomer (an 
oligomeric PEG with a nominal molar mass of 700 g/mol terminally functionalized on both end 
groups with an acryl or acryloxy functionality); a hydrophilic monomer used to make up the 
majority of the particle composition (tetraethylene glycol monoacrylae, HP4A); an amine 
containing monomer (aminoethyl methacrylate, AEM) which provides chemical handle to 
conjugate various linkers and peptides; and a photoinitiator, TPO. Pre-particle solution was 
composed of 69 wt% HP4A, 10 wt% PEG700DA, 20 wt% AEM, and 1 wt% TPO. Using # 3 mayer 
rod, a thin film of pre-particle solution was drawn on to corona-treated PET using roll-to-roll lab 
line (Liquidia Technologies) running at 12 feet per minute. The solvent was evaporated by heat 
guns. Then 80X80X320 nm, cylinder shaped mold was laminated to delivery sheet and passed 
through nip (80 psi, 12 feet per minute). After delamination, filled mold were cured by passing 
through UV LED lamp (λmax =395 nm, 30 psi N2, 12 feet per minute; Phoseon). Due to UV light 
initiated radical chain polymerization, monomers cross-linked into polymers to form a hydrogel. 
After cross-linking the hydrogels inside the mold cavities, filled mold was laminated against PVA 
harvesting sheet and passed through heated nip (140°C, 80 psi, 12 feet per minute). Particles 
were removed from mold by splitting the harvesting sheet from the mold. Particles were then 
harvested by dissolving sacrificial harvesting layer of PVA into water (2 ml of water per 10 feet of 
harvesting sheet). Particle suspensions were passed through 2 µm filter to remove additional 
scum layer. To remove excess of PVA, particles were spun down at 14,000 rpm (Eppendorf 
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Thermomixer R) for 25 minutes, and resuspended into sterile water. This purification procedure 
was repeated 3 times.  
3.2.2.2. Thermogravimetric analysis  
Concentrations of particles were determined by thermogravimetric analysis (TGA) using a TA 
Instrument’s Discovery TGA. Aluminum sample pans were tarred before loading the sample. 20 
µL of the stock nanoparticle solution were loaded on to the pan. Samples suspended in water 
were heated at 30 °C/min to 130 °C, followed by a 10 minute isotherm at 130 °C. All samples 
were then cooled at 30 °C/min to 30 °C, followed by a 2 minute isotherm at 30 °C.   
3.2.2.3. Scanning electron microscopy 
Particles were visualized by scanning electron microscopy (SEM) using a Hitachi S-4700 SEM. 
Prior to imaging, SEM samples were coated with 1.5 nm of gold-palladium alloy using a 
Cressington 108 auto sputter coater.  
3.2.2.4. Dynamic light scattering 
Particle size and zeta potential (ZP) were measured in sterile water by dynamic light scattering 
(DLS) on a Zetasizer Nano ZS (Malvern Instruments, Ltd.). 
3.2.2.5. Conjugation of linker to NPs 
We utilized amine groups from AEM to conjugate cleavable linkers, SPDP and NHS-
PEG(2k)OPSS.  Theoretical numbers of –NH2 groups contributed from 1 mg of nanoparticles 
suspension were calculated. Different molar ratios linker to amine groups (such as 0.28, 0.55 
and 2.30) were evaluated for the conjugation scheme (Table S1). For the optimized reaction 
scheme, particles were reacted with a 0.55 times molar excess of linker, resulting in reacting 1 
mg of NPs with 0.24 mg of SPDP or 6 mg of NHS-PEG-OPSS in 1 ml of 1X PBS + 0.1% PVA for 2 
hours. SPDP (or NHS-PEG(2k)OPSS) was dissolved in DMF. Volume of DMF kept constant at 
160 µL regardless of different linker mass used. Total volume of reaction was 1 mL. NPs were 
continuously agitated for 2 hours at 1400 rpm (Eppendorf Thermomixer R). After 2 hours, 
unconjugated linker was removed from the, pyridyldithiol decorated NPs via 2 centrifugation 
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washes (Eppendorf Centrifuge 5417g) with sterile water. Efficiency of linker conjugation was 
evaluated by incubating 1 mg of NPs in 1 mL of DTT solution. Moles of DTT used was 10 times 
higher than the moles of linkers added during conjugation procedure. Due to disulfide exchange 
reaction, pyridine 2 thione is released from pyridyldithiol modified NPs, which can be detected 
by reading absorbance at 343 nm using Spectra Max M plate reader. Conjugation efficiency was 
determined by the following formula: 
% Conjugation efficiency = (Amount of linker conjugated) X 100 / (Amount of linker 
charged)………(1) 
Conjugation efficiency of linkers were between 50-60%.  
3.2.2.6. Conjugation of CSIINFEKL to NPs 
Once NPs were modified with SPDP or NHS-PEG(2k)OPSS, they were spun down for 25 mins at 
14,000 rpm (Eppendorf Centrifuge 5417g) and resuspended into 800 µL of sterile water. 1 
mg/ml of cysteine labeled SIINFEKL (CSIINFEKL) solution was made in sterile water. 200 µL 
of this solution was mixed with 800 µL of NPs suspension and incubated overnight. NPs were 
continuously agitated at 1400 rpm (Eppendorf Thermomixer R). The following day, NPs were 
spun down for 25 mins at 14,000 rpm (Eppendorf Centrifuge 5417g), supernatant was collected 
and NPs resuspended in 1 mL of sterile water. To remove unbound peptide, NPs were washed in 
sterile water for 2 times. Due to disulfide exchange with cysteine labelled peptide, pyridine 2 
thione is released from pyridyl dithiol modified NPs. By reading the absorption of pyridine 2 
thione in the supernatant at 343 nm using Spectra Max M plate reader, the amount of pyridine 2 
thione released from NPs can be calculated and thus amount of peptide conjugated was 
evaluated. Conjugation efficiency of peptide was evaluated as mentioned by equation 1. We 
found 60-70% conjugation efficiency of peptide to NPs.  
3.2.2.7. Reduction and purification of C6 S-S- C6 CpG 1826 
CpG 1826 with phosphorothioate backbone was chosen because of slower in vivo degradation 
via nucleases as compared to CpG with phosphodiester [39]. C6 S-S- C6 CpG 1826 was reduced 
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with 100 mM DTT solution in sodium phosphate buffer of pH 8.0 and purified by gel filtration 
chromatography using Sephadex NAP-10 column. Unreduced CpG was kept for an hour in 
presence of 100 mM DTT solution in sodium phosphate buffer of pH 8.0. Sephadex NAP-10 
column (DNA grade) was equilibrated by flowing through 15 mL of sterile water (DNAse, RNAse 
free). After equilibration, 0.75 mL of sample was loaded to column and allowed to pass through 
completely. Reduced CpG was eluted by passing through 1.2 mL of water. Concentration of CpG 
was measured by evaluating absorption at 260 nm by using NanoDrop 2000 
Spectrophotometer.   
3.2.2.8. Conjugation of thiol-CpG 1826 to NPs 
Once NPs were modified with SPDP or NHS-PEG(2k)OPSS, NPs were spun down for 25 mins at 
14,000 rpm (Eppendorf Centrifuge 5417g)  and resuspended into 800 µL of sterile water. 40 µg 
of thiol CpG 1826 was mixed with 1 mg of linker modified NPs and kept for 8 to 10 hours. Total 
volume of reaction was 1 mL. NPs were continuously agitated at 1400 rpm (Eppendorf 
Thermomixer R). Then NPs were spun down for 25 mins at 14,000 rpm (Eppendorf Centrifuge 
5417g) and resuspended into 200 µL of 10X PBS. This washing procedure was repeated 3 times 
to remove adsorbed CpG. To evaluate conjugation of CpG, NPs were incubated in 100 mM DTT 
for 4 hours. NPs were spun down and supernatant was collected. Conjugation efficiency of CpG 
was evaluated as mentioned by equation 1. Evaluation of CpG was done by reading absorption at 
260nm using NanoDrop 2000 spectrophotometer. We found 70-80% conjugation efficiency of 
CpG to NPs.    
3.2.2.9. Co-conjugation of CSIINFEKL and CpG ODN to NPs 
CSIINFEKL peptide and CpG were co-conjugated in 2 step process. For co-conjugation process 
we used 0.39 mg of SPDP or 12 mg of NHS-PEG(2k)OPSS. After modified with linkers, NPs 
were conjugated to CSIINFEKL by incubating 1 mg of NPs with 0.2 mg of CSIINFEKL. Unbound 
peptides were removed by washing NPs in sterile water for 2 times. After the final wash 
nanoparticles were resuspended in 900 mL of sterile water and 0.04 mg of reduced CpG was 
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added and left to react for 8-10 hours at 1400 rpm (Eppendorf Thermomix R). After co-
conjugation, to evaluate peptide and adjuvant loading, CSIINFEKL and CpG were cleaved from 
NPs by incubating 1 mg of NPs with 100 mM DTT for 4 hours. After 4 hours, nanoparticles were 
spun down at 14,000 rpm (Eppendorf Centrifuge 5417g) for 25 mins, and the supernatant was 
evaluated for released peptide and adjuvant through HPLC Agilent 1200 Series and NanoDrop 
2000 spectrophotometer, respectively. Co-conjugation of adjuvant resulted in a reduction of 
final peptide loading to 50% conjugation efficiency, while CpG loading remained at 
approximately 50-60% conjugation efficiency.  
3.2.2.10. Peptide evaluation via HPLC 
Reverse phase high performance liquid chromatography (HPLC) was run on an Agilent1200 
series HPLC system using an Agilent C18 column. A Waters 2695 Alliance module equipped 
with quaternary pump, mobile phase degasser, temperature controlled auto sampler and 
column thermostat were used for HPLC analysis. The separation was carried out on a zorbax 
C18(2) column (150mm×4.6mm i.d., 3µm particle size, 100Å pore size) from Phenomenex 
(Torrance, CA) at column temperature of 50 oC and sample temperature of 50 oC. Peptide was 
eluted using mobile phase gradient, which consist of two solution. Solution A- Water (0.1% TFA- 
Triflouroacetic acid) and B- Acetonitrile with 0.1% TFA. Gradient method is shown in table-3.1. 
Table-3.1: Gradient method for HPLC run 
 
Min % of Mobile Phase 
A 
% of Mobile Phase 
B  
Flow rate (ml/min) 
0 100 0 2 
5  100 0 2 
25 5 95 2 
28 5 95 2 
30 100 0 2 
 
Binary linear gradients starting from a mixture of 100% A and 0% B from 0 min to 5 min. From 
5 min to 25 min B was increased gradually from 0% to 95%. Then, till 28 mins gradient was kept 
5% for A and 95% for B. The mobile phase composition was then changed back to initial solvent 
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mixture and the column was equilibrated for 2 min before every subsequent run. The flow rate 
of the mobile phase was set to 2.0 mL/min. The samples for HPLC injections were prepared by 
cleaving off peptide in 100mM DTT in sterile water. Peptides were detected via UV-VIS detector 
at 210 nm and concentration was determined by comparing area of peak with standard curve. 
Know amount of peptides were dissolved with 100mM DTT in sterile water to prepare standard 
curve.  
3.2.2.11. Animals  
Female C57BL/6 mice and OT-I TCR transgenic mice were purchased from Jackson Laboratory 
and used at age 6−12 weeks. All experiments involving mice were carried out in accordance with 
an animal use protocol approved by the University of North Carolina Animal Care and Use 
Committee. 
3.2.2.12. Preparation of single cell culture from mouse spleens  
Spleens were harvested from euthanized mice aseptically. Individual spleens were mechanically 
dissociated with back of the sterile syringe plunger through 100um cell strainer into RPMI 1640 
medium. Red blood cells were lysed by ACK buffer. Cells were then resuspended in R-10 
medium (RPMI 1640 medium supplemented with 10% FBS, 10 U/ml penicillin and 10 µg/ml 
streptomycin, 2mM L-Glutamine) and filtered through 70µm cell strainer to remove any 
residual tissue fragments.  
3.2.2.13. Preparation of BMDCs  
Bone marrow was collected from mouse femurs and tibias as reported [40]. Erythrocytes were 
lysed by ACK lysis buffer (Lonza). Bone marrow cells were then cultured at 2x106/ml in R10 
supplemented with 50 µM 2-mercaptoethanol, 10 ng/ml each of IL-4 and granulocyte–
macrophage-colony stimulating factor (GM-CSF). The culture was replenished with fresh 
medium on day 3 without removing old medium. On day 6 or 7, BMDCs were harvested and 
purified with Opti-Prep density medium (Sigma) to remove dead cells.    
3.2.2.14. Antigen presentation assay in BMDCs 
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To evaluate the effect of linker length on antigen presentation, Day 6 BMDCs (3×105 cells) were 
either untreated or treated with blank hydrogels (with and without linkers), CSIINFEKL (5 
µg/ml), CSIINFEKL conjugated to PEG hydrogels via SPDP (short cleavable linker, 5 µg/ml) or 
CSIINFEKL conjugated to PEG hydrogels via PEG (2k) OPSS (longer cleavable linker 5ug/ml) 
for 4 hours. After four hour incubation, cells were either washed with PBS of pH~7.4 or citrate-
phosphate buffer (pH3.0) for 3 minutes on ice to strip off the MHC-I-peptide complex or NP-
peptide/H-2Kb complex from cell surface. Additionally, cells  were re-incubated at 37oC for an 
additional 20 hours post-washes and then stained with CD11c-APC and 25-D1.16-PE (anti-
SIINFEKL/H-2Kb complex) antibodies (eBioscience), followed by flow cytometry analysis on 
Cyan ADP (Dako).   
3.2.2.15. In vitro T cell proliferation assay 
In vitro CD8+ T cell proliferation was done as previously reported [41]. Briefly, day 6 BMDCs 
were dosed with the samples described ablove for 24 h at 37C. OT-I CD8+ T cells were isolated 
from OT-I mouse spleens using CD8α+ T cell Isolation Kit (Miltenyi Biotec) as per 
manufacturer’s instructions and labeled with CFSE (5 µM) in PBS with 0.1% FBS for 10 min at 
37C. BMDCs were then incubate with OT-I-CFSE cells in R-10 medium for 72 h at 37C. After 
incubation, cells were stained with CD8 and Vα2 antibodies. Division of OT-I cells as indicated 
by dilution of CFSE fluorescence in T cells was examined by flow cytometry. 
3.2.2.16 BMDC maturation assay 
Day 6 BMDCs were treated with samples for 24 h at 370C. Cells were washed and stained with 
CD40-APC, CD80-FITC and MHC II-eFluor450 (ebioscience), then analyzed by flow cytometry. 
3.2.2.17. Immunization Study 
All formulations were prepared using low endotoxin grade reagents. To confirm the low 
endotoxin content of vaccines, formulations were routinely tested for endotoxin content using 
Pierce LAL Chromogenic Endotoxin Quantitation Kit following instructions. All formulations 
were prepared 24 hours before injections, resuspended in an isotonic 9.25% sucrose, and 
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subcutaneously administered in the right flank. SIINFEKL was given at a dose of 100 µg and 
CpG was injected at a dose of 20 µg. On day 7, mice were sacrificed, spleen and draining lymph 
nodes were harvested. All studies were repeated twice and each experimental arm contained 4-6 
mice. 
3.2.2.18. ELISPOT assay 
Frequency of antigen specific IFN- producing T cells in spleen was evaluated using IFN- 
ELISPOT kit (BD Biosciences). Immobilon-P hydrophobic PVDF plates (Millipore) were briefly 
treated with 35% ethanol, washed 2 times with PBS and coated overnight with anti-mouse IFN- 
antibody at 4oC. The following day, plates were blocked with 200µl R-10 medium with for 2hrs 
at room temperature (RT). 100,000 splenocytes in R-10 medium were plated in each well, with 
or without restimulation with 10 µg/ml of SIINFEKL peptide overnight at 37C. Spots were then 
developed following manufacturer’s instructions. 
3.2.2.19. In vivo CTL assay 
In vivo CTL assay was performed as previously reported [42]. Briefly, OT-I T cells were isolated 
from spleen using CD8α+ T cell Isolation Kit (Miltenyi Biotec). C57BL/6 mice were injected 
intravenously with 10,000 OT-I T cells on day -1. On day 0, mice were either untreated or 
immunized subcutaneously with a mixture of soluble SIINFEKL and CpG ODN, or NPs-SPDP-
CSIINFEKL-CpG, or NPs-PEG(2k)OPSS-CSIINFEKL-CpG. Fifteen days after vaccination, mice 
were intravenously injected with 5×106 splenocytes as target cells. To prepare target cells, 
splenocytes from wild type C57BL/6 mice were pulsed with SIINFEKL peptide at 1µg/ml in PBS 
for 1 h at 37C, washed with PBS, and labelled with CSFE at 4 µM in PBS for 10 min at 37C 
(CFSEhi); or non-peptide pulsed cells were labeled with CSFE at 0.4 µM in PBS for 1 h at 37C 
(CFSElo). CFSEhi and CFSElo cells were mixed at 1:1 ratio to generate target cells for i.v. 
injections. On day sixteen, mice were euthanized, splenocytes were isolated and cells were 
stained with anti-CD8 and Vα2 antibodies. Percentage of CFSEhi and CFSElo were determined 
with a flow cytometer.  The ratio of unpulsed to pulsed target cells in the naïve (unimmunized) 
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mice defined the 0% lysis level. The percent-specific lysis is determined by loss of the antigen-
pulsed CFSEhi population compared with the unpulsed CFSElo control population using the 
formula: [1− (ratio in naive mouse/ratio in experimental mouse)] × 100. 
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3.3. Results 
Figure-3.1: Conjugation of cleavable linkers and cysteine labelled SIINFEKL to PEG 
hydrogels. 
PEG hydrogels were first modified with cleavable linkers SPDP or NHS-PEG(2k)-OPSS.  NP-
linker conjugation was evaluted through the release of pyridine 2-thione after incubation of NPs 
with DTT.  Linker modified particles were incubated with CSIINFEKL, and peptide conjugation 
was evaluated through the release of pyrigine 2-thione.  
 
3.3.1. Conjugation of CSIINFEKL and CpG to NPs  
Pathogen inspired cylinder shaped (80×80×320 nm) cationic PEG hydrogel NPs were 
fabricated by PRINT® process. It has been established that particles with a net positive charge 
bind to the negatively charged plasma memberane of the cell surface, thus increasing cellular 
uptake, as well as enhance endosomal escape of cargos [43]. Our previous work demonstrated 
that cationic hydrogel particles were able to efficiently deliver siRNA to cytosol, resulting in 
efficient gene silencing [44, 45]. Furthermore, Fromen et al. demonstrated significanlty higher 
lung and systemic antibody titers when cationic particles were used to deliver ovalbumin, as 
compared to anionic particles [46]. Therefore, amine groups on NP surface were used to 
conjugate cysteine labelled SIINFEKL peptide via reduction sensitive, heterobifunctional 
linkers- SPDP or NHS-PEG(2k)OPSS in a two step-process (Figure 3.1). First, the succinimidyl 
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ester of the linker was reacted to the amine groups on the particle, forming an amide bond. The 
excess linker was then removed via centrifugation washes, followed by reacting the cysteine 
labeled adjuvant with the pyridine disulfide ring. Linker density was controlled by varying the  
Table-3.2: Physical Characterization of nanoparticles conjugated to SPDP.  
 
mg of 
SPDP 
loaded 
ratio of 
linker 
to -
NH2 
sites 
mg of 
SPDP 
conjugate
d 
% of NH-2 
conjugated 
%Conjugatio
n Efficiency 
Size 
(nm) 
PDI ZP 
(mV) 
0.12 0.28 0.10 23.00 83.33 269±8 0.04±0.03 36±5 
0.24 0.55 0.19 43.70 79.17 240±5 0.05±0.01 38±1 
1 2.30 0.47 108.11 47.16 251±1
5 
0.115±0.02
3 
-21± 
2 
 
linker-to-NP ratio (Table 3.2), in an effort to determine maximum linker density while 
maintaining  the positive charge of the nanoparticles. Thus during mono- or dual conjugation of 
antigenic peptide and CpG, we aimed to keep the overall charge of NPs positive (as indicated by 
zeta potential) to facilitate better uptake by APCs and to get possible endosomal escape of 
cargos. As shown in Table S1, as the amount of SPDP charged to the nanoparticle increased from 
0.12 mg to 1 mg, the conjugated amount of linker increased; however, conjugation efficiency 
decreased. At the highest level of SPDP charged, the ZP of NPs became negative (-21± 2 mV) 
indicating almost complete conversion of amine groups and therefore eliminating this 
formulation from further development. The amount of SPDP and NHS-PEG(2k)OPSS used for 
single component conjugation (either peptide or CpG) to modify 1 mg of NPs was 0.24 mg and 6 
mg, respectively, which resulted in positively charge particles. 
Particles modified with each linker were then incubated overnight with CSIINFEKL in 
sterile water, resulting in  peptide conjugation to the NPs via disulfide exchange. Followed by 
incubation with thiol-containing CpG (Figure 3.1). For co-conjugation reactions, conjugation 
efficiency for peptide and CpG was around 50% and 50-60%, respectively.  
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Following peptide and CpG modification, NPs remained highly uniform in size and shape 
as visualized by SEM (Figure 3.2). For all formulations the ZP remained greater than +25 mV 
(Table 3.3) which is desirable for cytosol delivery of antigens into MHC class I presentation 
pathway. Polydispersity index (PDI) of all sets of nanoparticles was found to be <0.1 which 
indicates monodisperse nanoparticles with homogenous distribution, and size ranged from 250-
280 depending on the surface modification. 
Table-3.3: Physical Characterization of PEG hydrogel sub-unit vaccine. (For all formulations, 
n=4) 
 
Formulations Size 
(nm) 
PDI ZP 
(mV) 
mg of 
linker/mg 
NP 
mg 
CSIINFE
KL/mg NP 
mg of 
CpG 
ODN / 
mg of 
NPs 
NPs (Blank) 274 ± 7 0.05 ± 0.01 38 ± 2 N/A N/A N/A 
NPs-SPDP 259 ± 
20 
0.05 ± 0.02 36 ± 4 0.1 ± 0.003  
to 
0.48 ± 0.040 
N/A N/A 
NPs-PEG  278 ± 9 0.04 ± 0.03 37 ± 1 0.283 ± 
0.016 
N/A N/A 
NPs-SPDP-
CSIINFEKL  
260 ± 
15 
0.04 ± 0.01 38 ± 2 N/A 0.093 ± 
0.01  
N/A 
NPs-PEG-
CSIINFEKL  
271 ± 4 0.04 ± 0.01 34 ± 2 N/A 0.08 ± 
0.001 
  
N/A 
NPs-SPDP-CpG  238 ± 5 0.03 ± 0.01 35 ± 2 N/A N/A 0.050 ± 
0.005 
NPs-PEG- CpG  289 ± 7 0.07 ± 0.02 30 ± 4 N/A N/A 0.048 ± 
0.006 
NPs-SPDP-
CSIINFEKL-
CpG 
246 ± 3 0.09 ± 0.02 26 ± 
11 
N/A 0.082 ± 
0.032 
0.017 ± 
0.007 
NPs-PEG-
CSIINFEKL-
CpG 
255 ± 7 0.04 ± 0.02 29 ± 
11 
N/A 0.071 ± 
0.013 
0.015 ±  
0.003 
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Figure-3.2: Representative SEM image of 
80x320 nm PRINT subunit peptide vaccine. 
 
 
 
 
 
3.3.2. In vitro antigen presentation in BMDCs by sub-unit vaccine 
 In order for vaccines to generate an efficient CD8+ T cell response, DCs must first 
internalize antigens, process them into 8-12 amino acid peptides and present them to T cell 
receptors as peptide/MHC-I complexes on cell surface. T cells recognize MHC-I-peptide 
complex via T cell receptors and in presence of other co-stimulatory signals subsequently 
proliferate. Since antigen presentation is key to developing an efficient T cell response, the 
antigen presentation efficiency of our PRINT NP subunit vaccine was evaluated using an in vitro 
assay. 25-D1.16, an antibody that recognizes SIINFEKL/H-2Kb on antigen presenting cells was 
used to stain BMDCs treated with various samples to quantify antigen cross presentation. As 
expected, SIINFEKL peptide binds to H-2Kb on the cell surface directly upon 4 hours pulsing, 
while treatment with blank NP-SPDP or NP-PEG(2k)OPSS and washes with PBS resulted in 
minimum staining for MHC-I-peptide complex (Figure 3.3A). Interestingly, cells treated with 
NP-SPDP-CSIINFEKL or NP-PEG(2k)OPSS-CSIINFEKL showed similar surface MHC-I-
peptide staining to soluble peptide (Figure 3.3A and Figure 3.3I). The kinetics of NP processing, 
antigen cleavage, internalization, and  MHC-I presentation make it unlikely that the high 
staining observed with NP-peptides after 4 hours incubation was all due to antigen cross 
presentation. Instead, the results suggest that SIINFEKL peptide displayed on NPs may bind to 
MHC class I H-2Kb on the cell surface and form the pMHC complex stainable by 25-D1.16. When 
unbound peptide or NP-peptide were removed by washes with PBS, followed by another 20 h  
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Figure-3.3: Enhanced antigen presentation by NP-peptide in BMDCs.  
BMDCs were treated with different formulations for 4 hours and washed with PBS (A), and 
incubated for another 20 hours (B), or washed with acidic citrate-phosphate buffer (pH3) (C), 
and incubated for another 20 hours (D). Representative flow cytometry histogram for each group 
is shown in figure 3.3A to 3.3D. The numbers in the histogram represents the percentage of 
CD11c+ dendritic cells that were positive for p/MHC I. Quantitative analysis of data (E-L). 
Results are shown as mean ± SD, n=3. E-G, data were analyzed by two-way anova, tukey’s post 
hoc analysis, I-L, data were analyzed by one-way Anova, holm’s sidak test, ** p < 0.01, *** p 
<0.001.   
 
culture at 37C, it was observed that both NP-SPDP-CSIINFEKL and NP-PEG(2k)OPSS-
CSIINFEKL led to significantly higher pMHC level than that of soluble peptide pulsed BMDCs 
(Figure 3.3B, Figure 3.3J). On the other hand, pMHC complexes on soluble peptide pulsed and 
washed BMDCs decreased over time, suggesting loss of pMHC (Figure 3.3E). These results 
indicate that NP-conjugation of antigenic peptide not only stabilizes cell surface MHC I through 
direct binding, but also increase the overall level of cell surface pMHC over time, possibly due to 
enhanced cell uptake of NP-peptides and more efficient delivery of antigenic peptide into class I 
presentation pathway. 
To further examine the capability of delivering antigenic peptide into cross-presentation 
pathway by NP-peptide formulations, cells were pulsed with soluble or NP conjugated peptides 
for 4 hours, and washed with an acidic citrate-phosphate buffer (pH3.0) for 3 minutes to strip 
off the MHC-I peptide complex from the surface of the BMDCs [47].  Cells were then incubated 
I J K L 
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for another 20 hours at 37C allowing for internalized antigens to be re-presented onto cell 
surface. As shown in figure-3.3C, 3.3F citrate-phosphate treatment completely removed 
SIINFEKL from pMHC complexes for cells treated with soluble SIINFEKL (down to 0.9%), but 
only partially removed cell bound NP-peptide (down to ~50%) (Figure 3.3K). This result may be 
due to the increased binding avidity of NP-peptide to cells as a result of multivalent binding of 
the peptide. As shown in Figure 3.3D, after acidic washes and an additional 20 hour incubation, 
peptide/MHC I staining for NP-SPDP-CSIINFEKL and NP-PEG(2k)OPSS-CSIINFEKL pulsed 
cells were 92.7% and 77%, up from around 50% (Figure 3.3G), which was also significantly 
higher than soluble SIINFEKL (6%) (Figure 3.3L). During the re-incubation period, cells treated 
with NP conjugated peptide had higher staining of pMHC complex, as compared to cells that did 
not go through re-incubation period (Figure 3.3G) which indicates higher uptake of NP and 
cross-presentation of antigenic peptide. In conclusion, the conjugation of peptide to PRINT NPs 
via cleavable linkers is able to achieve not only higher but also longer lasting cross-presentation 
of antigenic peptide by BMDCs as compared to soluble peptide.   
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3.3.3. In vitro proliferation of OT-I T cells in BMDCs treated with sub-unit vaccine 
 
 
 
 
 
 
 
 
 
Figure-3.4: T-cell proliferation assay. Peptide 
conjugated NPs induced higher T cell growth as 
compared to soluble peptide. BMDCs were incubated 
for 4 hours with free peptide and nanoparticulate 
peptide conjugated via short and long cleavable 
linkers. Pulsed BMDCs were then incubated with 
CFSE-labeled OT-I CD8+ T cells for 3 days. T cells 
were surface stained and proliferation of OT-I T cells 
were assessed by flow cytometry. A) Representative 
flow cytometry histogram of T cells treated with 
different formulations. B) Percentage of T cell 
growth after treatment with different formulations. 
Results shown as mean ± SD, n=3. Data were 
analyzed by one-way anova, bonferroni post hoc 
analysis, ** p < 0.01, *** p <0.001. 
 
Next, we evaluated how cross presentation via BMDCs translated into activation and 
priming of CD8+ T cells. CD8+ T cells derived from OT-I TCR transgenic mice were used to 
evaluate OVA-specific T cell response for NP and soluble vaccine formulations. In this study, 
BMDCs, either untreated or treated with soluble SIINFEKL or NP-SIINFEKLNP conjugated 
peptides were incubated with 5- (and 6-) carboxyfluorescein diacetate succinimidyl ester (CSFE) 
labelled OT-I T cells for three days. Proliferation of T cells was evaluated by flow cytometry. 
Representative flow cytometry histogram for each group is shown in figure 3.4A. As shown in 
A 
B 
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figure 3.4B, BMDCs pulsed with soluble peptide at concentration of 5 µg/ml were able to induce 
proliferation of cognate CD8+ T cells. In comparison, much enhanced T cell proliferation was 
observed for BMDCs treated with NP conjugated peptide, which indicates higher priming and 
activation of CD8+ T cells. CSIINFEKL conjugated to PRINT NPs via the longer cleavable linker 
resulted in approximately 95% of T cell growth, as compared to short cleavable linker (74.5%) 
and soluble peptide (32.6%). This is consistent with the enhanced antigen presentation by NP-
peptide demonstrated above (Figure 3.4B). 
3.3.4. Maturation of BMDCs by CpG ODN conjugated PEG hydrogels 
It is well known that activation of naïve T cells and development of multiple effector 
functions depends not only on recognition of MHC-I-peptide complex on APCs by TCRs, but 
also on a second signal from engagement of co-stimulation receptors. Concurrent delivery of 
adjuvants have been shown to promote the second signals, further drive clonal expansion of 
naïve T cells and aid in their differentiation into armed effector T cells.[17] The CD40 ligand and 
CD28 expressed on T cell surface bind to co-stimulatory molecules CD40 and CD80 on the 
surface of DCs, respectively. CD40 provides signals for activation, while CD80 provides signals 
for proliferation. The ability of PRINT NPs to deliver CpG ODN to provide co-stimulatory 
signals were tested in BMDCs. BMDCs were incubated with soluble CpG ODN or NP-CpG for 18 
hours. After incubation, cells were analyzed for expression of CD80 and CD40 via flow  
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Figure-3.5: Up-regulation of maturation markers by NP-CpG on BMDCs.  
BMDCs were treated with various samples for 24 hours with 1, 4 or 10 µg/ml of CpG.  
Equivalent amount of NPs were dosed in case of NP-peptide. NP-SPDP-CSIINFEKL (1) has 
equivalent dose of NPs to 1 µg/ml particulate CpG and NP-SPDP-CSIINFEKL (2) has 
equivalent dose of NPs to 10 µg/ml particulate CpG. The expression of co-stimulatory molecules 
were detected by flow cytometry analysis of fluorescence labelled CD40 and CD80 antibodies. 
Ratio of MFI from sample to MFI of untreated is plotted in A) for CD40 and B) for CD80. 
Results are shown here as mean ± SD, n=3. Data were analyzed by one-way anova, bonferroni 
post hoc analysis, *** p <0.001.  
 
cytometry. Expressions of co-stimulatory molecules were presented as a ratio of mean 
fluorescent intensity (MFI) to untreated cells. Treatment with CpG conjugated PRINT NPs at 1 
μg/mL or 10 μg/mL concentrations, induced upregulation of CD40 and CD80 on BMDCs as 
compared to untreated cells, as potently as soluble CpG. Therefore the functionality of CpG is 
well retained during conjugation to nanoparticles. No upregulation of either marker was found 
when BMDCs were treated with CSIINFEKL conjugated NPs. Lack of response indicates the 
limitation of delivering antigen alone for maturation of BMDCs. CD40 and CD80 were both 
upregulated when CpG ODN were combined with antigenic CSIINFEKL peptide either via co-
conjugation of CpG ODN and SIINFEKL on a single NP, or when delivered on separate NPs 
CD40 CD80 A B 
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(NP-CpG + NP-Peptide), indicating the helper effect of adjuvant in presence of antigen (Figure 
3.5A and B).  
3.3.5. Induction of IFN- producing SIINFEKL specific CD8+ T cells in mice 
After evaluating the efficiency of antigen presentation and maturation of BMDCs as well as OT-I 
T cell proliferation, PRINT NP subunit vaccines were analyzed for their efficacy to induce IFN- 
producing antigen specific T cells in mice. Frequency of antigen-specific IFN- producing T cells 
in spleens of mice 7 days post immunization was evaluated ex vivo by ELISPOT. First we 
evaluated whether co-conjugation of antigen and adjuvant are necessary by vaccinating mice 
with NP-SPDP-CSIINFEKL + NP-SPDP-CpG and NP-SPDP-CSIINFEKL-CpG.  
We found that mice treated with NPs co-conjugated to antigenic peptide and CpG 
induced significantly higher CD8+ T cell response as compared to mice treated with separately 
conjugated NPs (Figure 3.6). Similar results were also reported by Schlosser et al. when they co-
encapsulate TLR ligands- CpG or poly I: C and antigen in the same delivery system [48].  Next 
we tested both the vaccine formulations for their ability to induce IFN-ϒ producing CD8+ T 
cells. As shown in figure 3.7A, there is a significant difference in induction of IFN- producing 
CD8+ T cells when mice were immunized with NPs-SPDP-CSIINFEKL-CpG and NPs-
PEG(2k)OPSS-CSIINFEKL-CpG as compared to mice receiving a mixture of soluble antigen and 
adjuvant. Co-conjugation of adjuvant and antigen resulted in 10 times higher induction of IFN- 
producing T cells as compared to NPs conjugated to antigen alone. IFN- producing T cells 
response was minimum in case of negative control-blank PRINT NPs.   
Secretion of IFN- by antigen-specific CD8+ T cells into culture medium upon 
restimulation over 3 days was also examined by ELISA.  Similar to T cell frequency analysis, the 
bulk production of IFN- was also significantly higher for mice treated with NP formulations 
with co-conjugated peptide and adjuvant as compared to NP conjugated with just antigen, or 
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soluble antigen and adjuvant (Figure 3.7B), again confirming the importance of co-delivery of 
CpG adjuvant for IFN- production. 
 
Figure-3.6: Evaluation of IFN-γ producing CD8+ T 
cells: Separate vs co-conjugation of antigen and 
adjuvant.  
Co-conjugation of peptide and CpG ODN has induced 
higher numbers of IFN-γ producing SIINFEKL specific 
CD8+ T cells in spleen as compared to separate 
conjugation. Mice were immunized with various samples 
containing 100 µg peptide and/or 20 µg CpG via s.c 
injection in left flank. One week later, splenocytes were 
isolated and re-stimulated with SIINFEKL for 20 h for 
IFN-γ ELISPOT assay. Results are shown as mean ± SD, 
n=3-4. Data were analyzed by Student’s t-Test** p < 0.01. 
 
 
 
  
Figure-3.7: Induction of IFN- producing SIINFEKL specific CD8+ T cells in spleen. 
Mice were immunized with various samples containing 100 µg peptide and/or 20 µg CpG via s.c 
injection in left flank. One week later, splenocytes were isolated and re-stimulated with 
SIINFEKL for 20 h for IFN- ELISPOT assay (A), or for 72 h for ELISA analysis of secreted 
IFN- in medium (B). Results are shown as mean ± SD, n=4. Data were analyzed by one-way 
anova, Holm-Sidak’s multiple comparison test, *p < 0.05, *** p < 0.001.  
 
A B 
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3.3.6. In vivo CTL response in mice after immunization with SIINFEKL and CpG 
co-conjugated NPs 
 
Figure-3.8: In vivo CTL response after 
vaccination with model peptide hydrogel cancer 
vaccine.  
NPs-PEG(2k)OPSS-CSIINFEKL-CpG is more 
effective at killing target cells compared to NPs-
SPDP-CSIINFEKL-CpG. Purified OT-I CD8+ T 
cells were adoptively transferred into C57BL/6 
mice. Two days later, mice were kept a) untreated 
or immunized with either b) soluble SIINFEKL + 
soluble CpG or c) NPs-SPDP- CSIINFEKL-CpG or 
d) NPs-PEG OPSS-CSIINFEKL-CpG. Fifteen days 
later, CFSE labeled wild type splenocytes (non-
peptide pulsed CFSEhi and peptide pulsed CFSElo, 
1:1) were i.v. transferred into immunized mice. 
After twenty hours, splenocytes were isolated and 
population of target cells was determined by flow 
cytometry. Representative histogram analysis of 
untreated (A), soluble SIINFEKL + soluble CpG 
(B), NPs-SPDP-CSIINFEKL-CpG (C) and NPs-
PEG(2k)OPSS-CSIINFEKL-CpG (D).  Quantitation 
of specific lysis from flow cytometry data in A-D 
(E). Results are shown here as mean ± SD, n=4. 
Data were analyzed by one-way anova, Holm-
Sidak’s multiple comparison test, *p < 0.05, ** p < 
0.01, *** p < 0.001. 
 
Induction of CTLs is critical in generating an antitumor immune response. We evaluated 
PRINT NP subunit vaccines for their ability to induce CTLs. through an in vivo CTL assay [42]. 
Untreated NPs-PEG (2k) 
OPSS- 
CSIINFEKL-CpG 
Soluble SIINFEKL + 
Soluble CpG 
NPs-SPDP- 
CSIINFEKL-CpG  
C D B A 
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Fifteen days after immunizations with mixture of soluble SIINFEKL and soluble CpG or NP-
SPDP-CSIINFEKL-CpG or NP-PEG(2k)OPSS-CSIINFEKL-CpG, mice were adoptively 
transferred with SIINFEKL pulsed, CSFEhi and control non-pulsed, CSFElo target cells. On day 
sixteen, peptide pulsed and non-pulsed target cells in mouse spleens were differentiated by flow 
cytometry by two distinct population with high and low CFSE fluorescence (R5 and R4, 
respectively in Figure 3.8A-D).  CSFEhi population was decreased for peptide pulsed cells in 
mice immunized with a mixture of soluble peptide and soluble CpG (Figure 3.8B), NPs-SPDP-
CSIINFEKL-CpG (Figure 3.8C) and NPs-PEG(2k)OPSS-CSIINFEKL-CpG (Figure 3.8D). 
Moreover, the percentage of OVA specific cell killing was 90% for mice treated with NPs-PEG 
(2k) OPSS-CSIINFEKL-CpG, which is significantly higher than mice treated with soluble 
antigen with soluble adjuvant (35%) and NPs-SPDP-CSIINFEKL-CpG ODN (50%) (Figure 
3.8E). Results from these assays reveal that the longer linker is more efficient at in vivo target 
cell killing as compared to short linker.  
3.4. Discussion 
Here we have shown: i) successful co-conjugation via reduction sensitive linkers of 
model antigenic peptide-SIINFEKL and CpG ODN to hydrogel NPs; ii) delivery of CSIINFEKL 
via NPs to DCs that induced cross-presentation of SIINFEKL via MHC-I protein molecules and 
subsequently stimulated in vitro proliferation of OT-I T cells; iii) delivery of CpG ODN via NPs 
provided “adjuvanted” effect by inducing maturation of DCs as demonstrated by upregulation of 
CD80 and CD40; iv) co-delivery of CSIINFEKL and CpG ODN induced IFN-γ producing robust 
CD8+ T cells and v) co-delivery of CSIINFEKL and CpG ODN by reduction sensitive hydrogel 
system elicited potent CTLs that kill antigen specific target cells. 
Within last decade PRINT NPs have evolved into a unique delivery platform for various 
agents such as chemotherapeutics, fluorescent dyes, quantum dots, siRNA and proteins [44, 49-
51]. Due to the versatility of the PRINT platform, it has been employed to study the impact of 
various particle parameters in a biological system such as bio-distribution of intravenously 
59 
 
administered NPs as well as lymphatic trafficking of particles after intramuscular 
administration [52, 53]. Utilizing immunologically inert materials to mimic size, shape, and 
surface functionality of pathogens, PRINT provides an excellent platform to engineer subunit 
vaccines investigating various combinations of antigens and adjuvants to tune the immune 
response [54]. Galloway et al. showed enhanced humoral response when mice were treated with 
trivalent influenza protein adsorbed cationic PLGA PRINT particles [55]. In an effort to induce 
mucosal immune response, Fromen et al. showed higher antibody titers of ovalbumin protein 
when delivered via intranasal immunization by PRINT hydrogels [46]. Building this platform, 
the work presented herein is the first PRINT system to induce potent CTL response by co-
delivering antigenic peptides and CpG ODN through reduction sensitive linkers.  
Disulfide linkers have been widely used in antibody drug-conjugates (ADCs) to allow for 
release of chemotherapeutic drugs in intracellular reductive environment and delivering 
antigenic proteins [56]. Eby et al. conjugated ovalbumin to polymeric micelles via pyridyl 
disulfide. One advantage of this technique is that triggered release of the cargo only happens 
upon cellular internalization, due to the presence of various reductive enzymes in the endosome, 
lysosome, and cytosol. Therefore, employing reduction sensitive linkers to conjugate CpG ODN 
and SIINFEKL to NPs, we were able to deliver  CpG, resulting in stimulation of TLR-9 and the 
triggered release of co-stimulatory molecules to enhance T cell activation, while also  delivering 
SIINFEKL, to be cross-presented to the surface of APCs  (vacuolar pathway) [5]. More 
experimental studies are required to understand the mechanism of NP uptake, trafficking, and 
antigen release.    
Employing peptide antigens has many advantages including enhanced safety, specificity, 
and stability. Furthermore, synthesizing eight to nine amino acid peptides for MHC-I/ HLA 
binding domains is uncomplicated and can be readily synthesized in large quantities. Using 
defined peptide epitopes allows for the generation of  very specific arms of effector T cells 
without the health risk of inducing autoimmune or adverse reactions which may occur in 
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response to whole protein antigens [57]. Moreover, peptides can be chemically modified to 
improve their solubility, stability, and antigenicity. In our studies, the cysteine modification 
added to the peptide for conjugation purposes did not interfere with MHC I binding to 
SIINFEKL. However, ensuring peptide modification does not alter MHC binding will need to be 
investigated for each unique application to confirm the appropriate antigen/peptide is being 
presented [58].   
Another important parameter of PRINT hydrogel vaccine design is the positive surface 
charge provided by AEM in the composition. Cationic formulations enhance NP cellular 
internalization and endosomal escape thereby delivering cargo in the reductive environment of 
cytosol [44, 45] . Being able to take advantage of these cellular events should favor antigen cross 
presentation through the classical pathway. Neumann et al. has also reported inflammasome 
activation by cationic charged particles alone, which may potentially provide adjuvanticity and 
contribute to the high potency of our particle vaccines [59, 60]. Additionally, positively charged 
particles remain trapped at the injection site because of collagen fibers and negatively charged 
proteins (glycosaminoglycans) of extracellular matrix (ECM) [61]. Our previous study suggested 
80×80×320nm cationic particles have minimal lymphatic drainage [53]. Thus our NP vaccines 
most likely rely on the uptake by tissue resident DCs at the injection site for antigen 
presentation, such as migratory CD103+ DCs in peripheral tissues, a subset of DCs very potent in 
antigen cross presentation [5]. These results, uniquely and for the first time, demonstrate the 
ability to perform well-controlled mechanistic studies to investigate the effect of optimizing 
particulate vaccine parameters in terms of immune cell targeting, APC uptake/activation, and 
nanoparticle vaccine efficacy. 
3.5. Conclusion 
In summary, we have investigated the use of an engineered PEG hydrogel subunit 
vaccine to harness the power of our own immune system to generate CTLs to validate this 
approach in the fight against cancer. We have designed and developed a model platform NP sub-
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unit vaccine to co-deliver antigenic peptide and CpG ODN. These NPs were successfully 
internalized and processed by BMDCs, resulting in BMDC maturation, subsequent cross-
presentation of antigenic peptide, and induction of potent antigen-specific T cells. Taken 
together, results from this study provided a highly specific and effective platform to develop 
vaccines against infectious disease and cancer.  
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Chapter 4: Induction of Antitumor Protective Immune Response by Sustain 
Release Delivery of Antigen and Adjuvant*  
4.1. Introduction 
Harnessing the power of a patient’s own immune system to target, fight and eradicate 
cancer cells without destroying healthy cells is a highly attractive and innovative approach for 
cancer management. Despite many efforts made to develop successful cancer vaccines, translation 
of cancer vaccines to clinic is challenging. FDA approval of sipuleucel‑T (Provenge®, Dendreon 
Corporation, Seattle, USA) in April 2010 for the treatment of metastatic castration-resistant 
prostate cancer (mCRPC) has created lot of encouragement and promises in the field of active 
immunotherapy. Various types of cancer vaccines including cell (T cells, dendritic cell (DC) and 
tumor cell) based vaccines, subunit vaccines, and genetic vaccines, are being evaluated  in pre-
clinical and clinical studies [1, 2]. Among them, sub-unit vaccines provide very safe and effective 
way to induce protective immunity against cancer. T-cell epitope peptides identified from tumor 
associated antigens (TAA) and various immunostimulatory adjuvants such as TLR/NLR agonists 
can be delivered to induce potent CTLs (cytotoxic T-lymphocytes) as well as memory response 
against tumors [3, 4]. Due to advancements in the field of nanotechnology, particulate delivery of 
DNA, siRNA, chemotherapeutics, proteins, and peptides to the specific target tissue is now 
possible [5]. Nanoparticle carriers can improve solubility, bioavailability, and therapeutic index 
of protected cargo. They are able to protect proteins and peptide antigens from degradation, and 
deliver them to specific antigen presenting cells, resulting in higher cellular uptake, antigen cross-
presentation, and induction of cellular response. Many particulate delivery systems have been 
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explored in pre-clinical studies for the delivery of antigenic peptides and adjuvants for cancer 
vaccine [6, 7]. For particulate based vaccines, antigens and adjuvants can be either adsorbed, 
encapsulated, or conjugated to nanoparticles. Various labile and non-labile linkers have been 
utilized to conjugate antigens on the surface of NPs for intracellular delivery, resulting in 
improved antibody titers and induction of potent cellular immune response [8-13].   
Various cross-inkers are also used extensively in the antibody-drug conjugate (ADC) field, 
in which it was discovered that linker chemistry plays an important role in the overall safety, 
stability, and potency of the ADCs. Cleavable linkers such as disulfide, hydrazine, and dipeptides, 
are widely used in the ADC field to conjugate cytotoxic small molecules to antibodies for targeted 
drug delivery [14]. Although reduction sensitive (disulfide) and acid labile (hydrazine) linkers 
were designed to release the drug in the intracellular environment, they underwent rapid cleavage 
at off target sites. The half-life of various peptides conjugated to hemoglobin via disulfide bonds 
in 0.5 mM GSH is <1 hour (8-45 mins) [15]. It has become apparent that the reduced potency and 
higher adverse effects of disulfide linked ADCs is associated to its non-specific cleavage and drug 
release in circulation. Thus efforts have been made to design new linkers, to provide higher 
stability in circulation, decrease off-target adverse effects, and improve the antitumor activity. 
Sterically hindered disulfide linkers improved biological stability and antitumor activity of cargo 
as compared to un-hindered disulfide linkers [16, 17]. Furthermore, maleimide based linkers 
utilize a Michael addition reaction to link a reduced thiol, resulting in the formation of a stable 
thioether linkage [18]. In a seminal paper by Baldwin and Kiick, it was shown that thioether bonds 
undergo retro and exchange reactions in the presence of other thiol compounds at physiological 
pH and temperature [19]. Furthermore, they found that based upon the Michael donor’s 
reactivity,  the kinetics of the retro reactions and extent of exchange could be tuned from 20 hours 
to 80 hours in highly reductive environment (10 mM GSH) [19]. Moreover, in a comparative study 
done by Genentech and Immunogen, they found that thioether linked ADC’s had improved 
efficacy and pharmacokinetics, and reduced toxicity in mouse breast cancer models as compared 
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to disulfide linked ADC’s [20]. These findings resulted in FDA approval of the thioether linked 
ADC Kadcyla® in 2013 for the treatment of patients with HER2+ metastatic breast cancer. 
Thioether linkage is also used in another FDA approved ADC, Adcetris® (brentuximab vedotin) 
which is prescried for the treatment of relapsed Hodgkin Lymphoma[21]. These results provided 
the novel controlled release strategy to deliver drugs or biomolecules via thioether linkages. 
Antigens and/or adjuvants delivered via thioether linkage could provide more stable and 
controlled release of subunit vaccine components for prolong activation of immune cells. To this 
end, we have evaluated the effect of linker chemistry (disulfide versus thioether) on subunit 
vaccine efficacy. 
 Controlled or sustained release of antigen is possibly advantageous in the generation, 
maturation, and extension of immune responses [22-25]. To this point, Yumeki et al. has shown 
that cationized OVA adsorbed to DNA hydrogel NPs had sustained release of OVA for 24 hours 
and induced a better antitumor immune response as compared to the soluble OVA protein [26]. 
Zhang et al. has also shown persistent antibody titer up to 10 weeks by providing sustain release 
of CpG ODN and OVA up to 60 days when encapsulated within PLGA micro-emulsions [27]. In 
chapter 3, we have shown the design of PRINT based NPs to co-deliver of CSIINFEKL and CpG 
ODN by conjugating them to NPs via disulfide linkers. These NPs were successfully internalized 
and processed by BMDCs resulting in antigen cross-presentation, maturation of BMDCs, and 
induction of antigen specific IFN-γ producing potent CD8+ T cells. In the studies presented 
herein, we have generated a better antitumor protective response through sustained release of 
model antigenic peptide CSIIFENKL and CpG ODN linked to NPs through thioether linkage, as 
compared to the same subunit vaccines utilizing disulfide linkage. We compared the in vitro and 
in vivo efficacy of PRINT subunit vaccines as a function of cargo release. For these studies, both 
antigen and adjuvant were conjugated to NPs either through disulfide linkage or thioether 
linkage. CSIINFEKL peptide release in highly reductive environment (10 mM GSH) were 
evaluated for each formulation. We further compared the formulations for their efficiency in 
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antigen cross-presentation in BMDCs, activation and maturation of BMDCs, as well as induction 
of antigen specific TNF-ϒ producing CD8+ T cells. Lastly, both formulations were evaluated for 
their potency to provide protection against tumor challenge in EG7 mouse tumor model. Our work 
demonstrates better antigen cross-presentation in BMDCs, as well as better activation and 
maturation of BMDCs treated with thioether formulation as compared to disulfide formulation. 
These enhancements translated to a 2-fold improvement in tumor growth inhibition for mice 
treated with the thioether formulation over the disulfide formulation.  
4.2. Materials and Methods 
4.2.1. Materials 
Poly (ethylene glycol) diacrylate (Mn 700) (PEG700DA), 2-aminoethyl methacrylate hydrochloride 
(AEM), diphenyl (2, 4, 6-trimethylbenzoyl)-phosphine oxide (TPO), thiol modified CpG 1826 (C6-
S-S-C6-tccatgacgttcctgacgtt), dithiothreitol (DTT), sucrose and DNase, RNase free sterile water 
were purchased from Sigma-Aldrich. Tetraethylene glycol monoacrylate (HP4A) was synthesized 
in house. Cysteine modified OVA257-264 (CSIINFEKL) were purchased from Peptide 2.0. 
Trifluoroacetic acid, methanol, dimethyl sulfoxide (DMSO), PTFE (polytetrafluoroethylene) 
syringe filters (13-mm membrane, 0.22-μm pore size), HPLC grade water and acetonitrile were 
obtained from Fisher Scientific. Conventional filters (2-μm) were purchased from Agilent 
Technologies, and polyvinyl alcohol (Mw 2000) (PVOH) was purchased from Acros Organics. (N-
Succinimidyl 3-(2-pyridyldithio)-propionate (SPDP) and SMCC (succinimidyl 4-(N-
maleimidomethyl) cyclohexane-1-carboxylate) were purchased from Thermo Scientific. PRINT 
molds (80 nm × 320 nm) were obtained from Liquidia Technologies. DNA grade NAP-10 columns 
were purchased from GE Healthcare. RPMI1640 medium, penicillin and streptomycin, L-
glutamine, fetal bovine serum (FBS) were all from Life Technologies.  
4.2.2. Methods 
4.2.2.1. PRINT nanoparticle fabrication 
PRINT nanoparticles were fabricated as mentioned in 3.2.2.1.  
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4.2.2.2. Thermogravimetric analysis  
Thermogravimetric analysis was performed as mentioned in 3.2.2.2. 
4.2.2.3. Scanning electron microscopy (SEM) 
SEM was performed as mentioned in 3.2.2.3. 
4.2.2.4. Dynamic light scattering 
Particle size and zeta potential were measured in sterile water by dynamic light scattering (DLS) 
on a Zetasizer Nano ZS (Malvern Instruments, Ltd.). 
4.2.2.5. Conjugation of linker to NPs 
We utilized amine groups from AEM to conjugate SPDP and SMCC.  Conjugation of SPDP to NPs 
was performed as mentioned in 3.2.2.5. For reaction of NPs with SMCC, equal moles of SMCC as 
to SPDP (0.26 mg of SMCC) was reacted to NPs in 1 ml of 1X PBS + 0.1% PVA for 2 hours. SMCC 
or SPDP were dissolved in DMF. Similar protocol was followed as mentioned in 3.2.2.5.  
4.2.2.6. Conjugation of CSIINFEKL to linker modified NPs 
Conjugation reaction of CSIINFEKL via SPDP was performed as mentioned in 3.2.2.6. Similar 
protocol was followed to conjugate CSIINFEKL to NPs via SMCC except conjugation reaction was 
done in 1X PBS.  At the end of the conjugation process, loading of SMCC conjugated peptide was 
evaluated by performing standard BCA assay (Thermo Scientific) on particle conjugated peptides. 
Loading of SPDP conjugated CSIINFEKL was evaluated by utilizing HPLC technique. Conjugation 
efficiency of peptide was evaluated using the following equation. 
% Conjugation efficiency = (Amount of linker conjugated) X 100 / (Amount of linker 
charged)……………………………………………………………………………………………………………………… (1) 
Conjugation efficiency of peptide is around 60-70% for both the linkers.  
4.2.2.7. Reduction and purification of C6 S-S- C6 CpG 1826 
Reduction and purification of C6 S-S- C6 CpG 1826 was done as mentioned in 3.2.2.7.  
4.2.2.8. Conjugation of Thiol-CpG 1826 to NPs 
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Conjugation of CpG ODN to NPs via SPDP was done by following procedure mentioned in 3.2.2.8. 
Similar protocol was followed to conjugated CpG ODN to NPs via SMCC except conjugation of 
CpG was performed in 1X PBS instead in sterile water. For both the formulations, evaluation of 
CpG was done via UV/VIS spectroscopy at 260 nm by using NanoDrop 2000 Spectrophotometer 
as mentioned above.       
4.2.2.9. Co-conjugation of CSIINFEKL and CpG ODN to NPs 
Co-conjugation of CSIINFEKL and CpG ODN to NPs via SPDP was done by following procedure 
mentioned in 3.2.2.9. Similar protocol was followed to co-conjugate CSIINFEKL and CpG ODN 
to NPs via SMCC except that conjugation was performed in 1X PBS instead of sterile water.  
Disulfide liked CSIINFEKL was evaluated via HPLC as mentioned in 3.2.2.10.  SMCC linked 
CSIINFEKL was evaluated via standard BCA assay (Thermo Scientific). Blank reading for BCA 
assay was taken in SMCC modified NPs. For both the formulations, evaluation of CpG was done 
via UV/VIS spectroscopy at 260 nm by using NanoDrop 2000 Spectrophotometer as mentioned 
above.   
4.2.2.10. Peptide release study 
CSIINFEKL was conjugated to nanoparticles via SPDP and SMCC as mentioned earlier. After 
conjugation of peptide, 5 mg of NPs were incubated in 10mM GSH (sterile water of pH 7.0) at 37o 
C. pH of the solution was adjusted to 7.0 by using 4 µM sodium hydroxide.  (One of the reason to 
use sterile water is because peptide is insoluble in buffer because of higher salt concentration). 
80uL of aliquot were collected at 0.5, 1, 2, 8, 24, 48 and 72 hours. Collected samples were spun 
down at 14000 RPM and supernatant were collected. Quantity of released peptide in the 
supernatant was evaluated by HPLC-MS. 
4.2.2.11. Peptide evaluation via HPLC 
Quantification of CSIINFEKL was done by HPLC as mentioned in 3.2.2.10.  
4.2.2.12. Liquid chromatography- Mass spectrometry (LC-MS) 
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Reverse phase high performance liquid chromatography (HPLC) was run on an Agilent1200 
series HPLC system equipped with quaternary pump, mobile phase degasser, temperature 
controlled auto sampler and column thermostat. The separation was carried out on a Zorbax 
Eclipse XDB-C18 (100 mm×2.1 mm i.d., 3.5 µm particle size) from Agilent Technologies (Santa 
Clara, CA) at column temperature of 40 oC. Peptide was eluted using mobile phase gradient at a 
flowrate of 300 µL/ min. Mobile phase consist of two solutions. Solution A- Water with 0.1% 
formic acid and B- Acetonitrile with 0.1% formic acid. Gradient method is shown in table-4.1. 
Table-4.1: Gradient method for LC-MS run 
 
Min % of Mobile Phase A % of Mobile Phase B  
0 98 2 
1 98 2 
17 50 50 
18 5 95 
23 5 95 
24 98 2 
30 98 2 
 
An Agilent 6520 Accurate Mass Quadrupole Time-of-Flight Mass Spectrometer (Q-TOF LC/MS) 
system was used for the detection of peptide species. Separated peptide species from the C18 
column were analyzed with electrospray ionization (ESI) in positive ion mode by scanning the 
instrument over the mass range of 100-3000 amu. 
4.2.2.13. Animals  
Female C57BL/6 mice were purchased from Jackson Laboratory and used at age 6−12 weeks. All 
experiments involving mice were carried out in accordance with an animal use protocol approved 
by the University of North Carolina Animal Care and Use Committee. 
4.2.2.14. Preparation of splenocytes and WBCs 
Splenocytes were isolated as mentioned in 3.2.2.12. To isolate leukocytes from blood, mice were 
bled submandibularly into 500 µl PBS with 7 mM EDTA. Diluted blood was then laid onto 500 µl 
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Lympholyte-mammal (Cedarlane) and spun at 600 g for 20 min. White blood cells were collected 
from the layer at the interface, washed with DPBS.  
4.2.2.15. Preparation of BMDCs  
BMDCs were prepared and cultured as mentioned in 3.2.2.13.  
4.2.2.16. Antigen presentation assay in BMDCs 
To evaluate the effect of linker chemistry on antigen presentation, Day 6 BMDCs (3×105 cells) 
were either untreated or treated with blank hydrogels (with and without linkers), CSIINFEKL (5 
µg/ml), CSIINFEKL conjugated to PEG hydrogels via SPDP (short cleavable linker, 5 µg/ml) or 
CSIINFEKL conjugated to PEG hydrogels via PEG (2k) OPSS (longer cleavable linker 5ug/ml) for 
4 hours. After four hour incubation, cells were either washed with PBS of pH~7.4 or citrate-
phosphate buffer (pH3.0) for 3 minutes on ice to strip off the MHC-I-peptide complex or NP-
peptide/H-2Kb complex from cell surface. Additionally, cells  were re-incubated at 37oC for an 
additional 24 hours, 48 hours and 72 hours post-washes and then stained with CD11c-APC and 
25-D1.16-PE (anti-SIINFEKL/H-2Kb complex) antibodies (eBioscience), followed by flow 
cytometry analysis on Cyan ADP (Dako).   
4.2.2.17 BMDC maturation assay 
BMDC maturation assay was performed as mentioned in 3.2.2.16. 
4.2.2.18. Immunization Study 
7 days immunization studies were performed as mentioned in 3.2.2.17. 
4.2.2.19. ELISPOT assay 
Enzyme-linked immunospot assay was performed as mentioned in 3.2.2.18. 
4.2.2.20. Tumor challenge study 
C57BL/6 mice were vaccinated subcutaneously with different formulations on day -28 and day -
7, respectively. Seven days after booster dose, on day zero, 9.3 x 105 EG7 cells were subcutaneously 
injected in the left flank region. Tumors were measured using digital calipers (Thermo Fisher 
Scientific, Pittsburgh, PA) every 2−3 days, recording the longest diameter as length and the 
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perpendicular dimension as width. Tumor volume was calculated as (0.5 × length × width × 
height). All the mice were euthanized humanely once untreated mice were reached tumor burden 
i.e. 20mm in measurement in either dimensions. At the end of study splenocytes were harvested 
and SIINFEKL specific IFN-γ producing T cells (from spleen) were evaluated via ELISPOT assay.  
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4.3. Results 
4.3.1 Conjugation of CSIINFEKL and CpG to NPs  
 
 
 
 
 
 
 
 
 
 
 
 
Figure-4.1: Co-conjugation of CSIINFEKL and CpG ODN to NPs via SPDP. 
NPs were first modified with SPDP. Pyridyl disulfide modified particles were incubated with 
CSIINFEKL and then with CpG ODN. Evaluation of CSIINFEKL and CpG ODN conjugated to 
NPs were performed by HPLC and absorption spectroscopy, respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-4.2: Co-conjugation of CSIINFEKL and CpG ODN to NPs via SMCC. 
NPs were first modified with SMCC. Maleimide modified particles were incubated with 
CSIINFEKL and then with CpG ODN. Evaluation of CSIINFEKL and CpG ODN conjugated to 
NPs were performed by BCA protein assay and absorption spectroscopy, respectively.  
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Amine groups on NP surface were used to conjugate cysteine labelled SIINFEKL peptide 
via reduction sensitive, heterobifunctional linkers- SPDP (Figure 4.1) or SMCC (Figure 4.2) in a 
two step-process. First, the succinimidyl ester of the linker was reacted to the amine groups on 
the particle, forming an amide bond. After removal of the excess linker (via centrifugation 
washes), the cysteine labeled adjuvant was reacted with either the pyridine disulfide of the SPDP 
linker or maleimide ring of the SMCC linker. Particles were modified with equal moles of SMCC 
and SPDP to ensure similar linker densities and particle surface charge. After modification with 
either of linkers, NPs were then incubated overnight with CSIINFEKL resulting in  peptide 
conjugation to the NPs via disulfide exchange (for SPDP) or Michael addition (for SMCC)followed 
by incubation with thiol-containing CpG.  
 
 
Figure-4.3: SEM image of 80×320 nm PEG hydrogel.  
 
 
 
 
 
 
 
 
 
 
Table-4.2: Physical Characterization of NPs 
 
Formulations Size (nm) PDI ZP (mV) 
NP-SPDP-
CSIINFEKL-CpG 
246 ± 3 0.09 ± 0.02 
 
26 ± 11 
 
NP-SMCC-
CSIINFEL-CpG 
270 ± 9 
 
0.12 ± 0.09 
 
24 ± 10 
 
 
After peptide and CpG modifications, NPs remained highly uniform in size and shape as 
visualized by SEM (Figure 4.3). For all formulations the ZP remained around +25 mV (Table 4.2) 
which is desirable for cytosol delivery of antigens into MHC class I presentation pathway. 
Polydispersity index (PDI) of all sets of nanoparticles was around 0.1 which indicates 
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monodisperse nanoparticles with homogenous distribution, and size ranged from 240-270 
depending on the surface modification. 
4.3.2. Release of antigenic peptide from NPs in highly reductive environment (10 
mM GSH) 
Release profiles of CSIINFEKL in highly reductive environment was evaluated by 
incubating the peptide modified particles (5 mgs) in 10 mM GSH (sterile water, pH 7.0) at 37o C. 
At various time points, aliquots of equal volume were collected and the quantity of released 
peptide was evaluated by HPLC-MS. Data from HPLC-MS analysis revealed three major species 
of peptide in the mixture, (a) free peptide, CSIINFEKL, b) glutathione bound peptide, GSH-
CSIINFEKL and c) peptide dimer, LKEFNIISC-CSIINFEKL. CSIINFEKL conjugated through the 
disulfide linker had rapid release profile in first 2 hours, with an initial burst release of 80% in 1 
hour (Figure 4.4). 
Figure-4.4: Release of 
antigenic peptide 
CSIINFEKL from NPs  
CSIINFEKL conjugated NPs 
were incubated in 10mM GSH 
(sterile water of pH 7.0) at 37o 
C. Samples were collected at 
different time points and 
quantity of released peptide 
was measured by HPLC. 
Percentage release of A) total 
peptide and B) 3 major species 
of CSIINFEKL. Thioether 
bonded peptide has relatively 
slower release profile as 
compared to disulfide bonded 
peptide. Results are shown as 
mean ± SD, n=2.  
 
Similarly, Trimble et al. reported rapid release of angiotensin II analog N-acetly-CGDKVYIHPF 
in 0.5 mM GSH with an half-life of 8-45 mins, when conjugated to hemoglobin via disulfide linker 
[15]. In comparison, thioether linked CSIINFEKL had a very stable and sustained release profile 
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till 72 hours (Figure 4.4), with a maximum of ~60% released in 8 hours. As seen in figure 4.4, 
release of total peptide (i.e. CSIINFEKL + GSH-CSIINFEKL + LKEFNIISC-CSIINFEKL) 
remained relatively constant and stable for thioether linked CSIINFEKL. Surprisingly, we found 
decrease in total peptide (i.e. CSIINFEKL + GSH-CSIINFEKL + LKEFNIISC-CSIINFEKL) release 
after 8 hours when CSIINFEKL was conjugated to NPs via disulfide linker (figure 4.4). This is due 
to the present of other peptide species with glutathione in the supernatant overtime. This was 
further confirmed by identifying different possible species (such as CSIINFEK, FNIISCCSIIN, 
GSH-CSIINFEK and FNIISCCSIINFEKL) present in the mixture by performing time of flight 
(TOF) mass-spec analysis on 0.5 hrs and 48 hrs samples from both the formulations as shown in 
Appendix Figure 1-6. We found similar species (peptide fragments) from both samples which 
could be due to interactions of released peptide fragments with other peptide fragments or with 
GSH. Presence of different peptide fragments in higher amount in the samples of NP-SPDP-
CSIINFEKL as compared to NP-SMCC-CSIINFEKL could be due to rapid release of CSIINFEKL 
from disulfide linked NPs which possibly resulted into decrease in total peptide. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
80 
 
4.3.3 Cross-presentation of CSIINFEKL in BMDCs 
 
 
 
 
Figure-4.5: Modified antigen presentation assay in BMDCs.  
BMDCs were treated with different formulations for 4 hours and washed with PBS (A), or washed 
with acidic citrate-phosphate buffer (pH3) (B, C, D, E), and certain acidic buffer washed samples 
F G 
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were further incubated for another 24 h (C), 48 h (D) and 72 h (E). Representative flow cytometry 
histogram for each group is shown in figure 4.5A to 4.5E. The numbers in the histogram represents 
the percentage of CD11c+ dendritic cells that were positive for pMHC I. Results are shown as 
mean ± SD, n=3. Data of pMHC I staining after 4 hours post PBS treatment were analyzed in (F) 
via one-way Anova, Tukey’s post comparison test. Readings of 4 h acid treated cells were 
subtracted from 24 h, 48 h and 72 h acid treated cells. Data was analyzed by two-way anova, 
tukey’s post hoc analysis, **** p <0.0001  
 
In the event of infection, DCs collect pathogens from peripheral sites and process them 
into small peptide fragments, which then bind to MHC-I/II molecules in endosome or ER 
(endoplasmic reticulum) and are transported back to the surface of DCs. CD4+ or CD8+ T cells can 
recognize these MHC I/II-peptide complexes via TCR (T cell receptors) and receive signals for 
proliferation. As shown in figure-2, when exposed to intracellular concentrations of GSH, 
CSIINFEKL bound to NPs via SMCC had a slower and more stable release profile as compared to 
CSIINFEKL bound by SPDP. It was hypothesized that this difference in release profile would 
result in linker specific pattern of cross-presentation of antigenic peptide overtime for BMDCs 
treated with the particulate vaccines. Prolongation of antigen presentation was evaluated via 
antigen presentation assay as mentioned in method section. BMDCs were either untreated or 
treated with soluble CSIINFEKL, NP-SPDP-CSIINFEKL, or NP-SMCC-CSIINFEKL for 4 hrs and 
washed with PBS. To quantify the antigen cross-presentation, BMDCs were stained with the 25-
D1.16 antibody which recognizes SIINFEKL/H-2Kb on APCs. As seen in Figure 4.5A and F, 
staining of p-MHC-I complexes was significantly higher in BMDCs treated with soluble 
CSIINFEKL and NP-SPDP-CSIINFEKL as compared to BMDCs treated with NP-SMCC-
CSIINFEKL. Most likely, the higher antigen presentation in BMDCs at early (4h) time points is 
due to the rapid release of CSIINFEKL from the disulfide linked NP.  
To further examine the mechanism of the NP-peptide formulations to deliver antigenic 
peptide, BMDCs were treated with soluble CSIINFEKL, NP-SPDP-CSIINFEKL, or NP-SMCC-
CSIINFEKL, and washed with acidic citrate-phosphate buffer (pH3.0) for 3 minutes to strip off 
the MHC-I peptide complex from the surface of the BMDCs [28]. Cells were then incubated at 
370C for another 24 hrs, 48 hrs and 72 hrs to allow for internalized antigens to be processed and 
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re-presented onto the cell surface. As shown in Figure 4B, citrate-phosphate treatment completely 
removed SIINFEKL from p-MHC complexes for cells treated with soluble SIINFEKL (down to 1.4 
%), but was unable to completely remove cell bound NP-peptide (Figure 4.5B). For cells treated 
with NP-SMCC-CSIINFEKL, the staining of p-MHC-I complexes was reduced to 13%, but was 
only decreased to 51% for cells treated with NP-SPDP-CSIINFEKL. This could be due in part to 
differences in avidity of the particulate bound peptide. Therefore, in an effort to find the absolute 
change in the antigen presentation, the percentage of p-MHC-I complex staining at 4 hrs after 
acid treatment was subtracted from the percentage of p-MHC-I complex staining at the later time 
points. At each time point, particle conjugated CSIINFEKL induce significantly higher antigen 
presentation in BMDCs as compare to soluble SIINFEKL. A gradual increase in antigen cross-
presentation was observed for both NP formulations over time after acid treatment, (Figure 4.5C, 
D, E) with 10-15% higher cross-presentation over time for cells treated with NP-SMCC-
CSIINFEKL than cells treated with NP-SPDP-CSIINFEKL (Figure 4.5G).  This is in direct 
agreement with the release rates observed in Figure 2, the slower release from the thioether bond 
results in prolonged antigen release and higher bioavailability of full peptides, and therefore 
improved antigen presentation over time. 
4.3.4 Maturation of BMDCs by particulate conjugated CpG ODN 
Activation of naïve T cells through recognition of MHC-I-peptide complex on APCs can be 
enhanced through the simultaneous delivery of adjuvants, which can further drive clonal 
expansion of naïve T cells and aid in their differentiation into armed effector T cells. The CD40 
ligand and CD28 on T cell surfaces can bind to co-stimulatory molecules such as CD40 and CD80 
on the surface of DCs. Maturation of DCs with upregulation of these co-stimulatory molecules is 
necessary for T cell activation and proliferation. The ability of particulate vaccines to deliver CpG 
ODN and provide co-stimulatory signals as a function of linker chemistry was tested in BMDCs. 
BMDCs were incubated with soluble CpG ODN or NP-CpG for 18 hours. After incubation, cells 
were analyzed for  
83 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-4.6: Up-regulation of maturation markers by NP-CpG on BMDCs.                       
BMDCs were treated with various samples for 24 hours with 1 µg/ml of CpG.  Equivalent amount 
of NPs were dosed in case of NP-SPDP and NP-SMCC. The expression of co-stimulatory 
molecules were detected by flow cytometry analysis of fluorescence labelled CD80 and CD40 
antibodies. Flow cytometry histograms for all the samples including both markers are shown in A. 
Ratio of MFI from sample to MFI of untreated is plotted in B) for CD40 and C) for CD80. Results 
are shown here as mean ± SD, n=3. Untreated cells were compared with cells treated with NP-
CpG. Data were analyzed by one-way anova, Holm-Sidak’s multiple comparison test, **** p 
<0.0001.  
B C 
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expression of CD80 and CD40 via flow cytometry. Flow cytometry histogram for both markers 
are shown in Figure-4.6A. Expressions of co-stimulatory molecules were presented as a ratio of 
mean fluorescent intensity (MFI) to untreated cells. Treatment with CpG conjugated PRINT NPs 
at 1 μg/mL concentration, induced upregulation of CD80 (Figure 4.6B) and CD40 (Figure 4.6C) 
on BMDCs as compared to untreated cells. Upregulation of CD80 induced by NP-SPDP-CpG and 
NP-SMCC-CpG was as potent as soluble CpG. Moreover, expression of CD40 was higher in cells 
when they were treated with NP-SMCC-CpG as compared to NP-SPDP-CpG which could be due 
to the extended release of CpG in intracellular reductive environment.  
4.3.5 In vitro release of IL-6 by BMDCs treated with NP conjugated CpG 
   
Figure-4.7:  Secretion of IL-6 from BMDCs treated with particulate conjugated CpG. 
BMDCs were treated with various samples for 24 hours with 1 µg/ml of CpG.  Equivalent amount 
of NPs were dosed in case of NP-SPDP and NP-SMCC. At the end of 24 hours, cells were spun 
down, media were collected and replaced with fresh media. Cells were kept growing for another 
24 hours and then media were collected. The release of IL-6 in media was detected by ELISA 
assay on collected media. IL-6 concentrations in pg/ml for 24 hours and 48 hours are shown in A) 
and B), respectively. Results are shown here as mean ± SD, n=3. Cells treated with NP-SPDP-
CpG were compared with cells treated with NP-SMCC-CpG by two-tailed, unpaired, Student’s t-
test, **** p <0.0001. 
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Cytokines play a central role in maintaining the homeostasis of CD8 T lymphocytes. IL-6 is a pro-
inflammatory cytokine which plays a very critical role in T cell activation, proliferation and 
survival [29]. IL-6 can stimulate TCR-independent proliferation and functional differentiation of 
CD8+ T cells, and synergize with TCR signals to augment CD8+ T cell proliferation [30]. CpG ODN 
has been shown to stimulate DCs by inducing secretion of IL-6 [31]. NP bound CpG was evaluated 
for its ability to stimulate the secretion of IL-6. The release of IL-6 by BMDCs were performed by 
treating BMDCs with various CpG formulations at a concentration of 1µg/ml for 24 hours. After 
24 hours, cells were spun down and supernatant collected. To evaluate whether different 
formulations would have prolonged effect on IL-6 release, cells were replenished with fresh media 
after 24 hours and incubated at 370C for another 24 hours. ELISA was performed to determine 
the concentration of released IL-6 at each time point. Concentrations of IL-6 are shown in figure 
4.7 A) for 24 hours, and in figure 4.7 B) for 48 hours. After 24 hours, cells treated with soluble 
CpG or particulate CpG secreted similar amounts (~2500 pg/ml) of IL-6 proving that CpG 
retained its activity after conjugation to NPs. Although at the 48 h time point the concentrations 
of secreted IL-6 were lower for NP-CpG as compared to soluble CpG, the level of released IL-6 
from BMDCs treated with NP-SMCC-CpG remained higher than the cells treated with NP-SPDP-
CpG. This further supports the evidence that slower and prolong release of adjuvant can produce 
higher effects.  
4.3.6 In vivo induction of antigen specific IFN-γ producing CD8+ T cells 
Both formulations were analyzed for their efficacy to induced SIINFEKL specific IFN-γ 
producing CD8+ T cells in mice. Frequency of IFN-γ producing CD8+ T cells were analyzed by 
performing ex vivo ELISPOT assay on isolated splenocytes and WBCs. As shown in Figure-4.8A 
and 4.8B, there is a significant difference in induction of IFN- producing CD8+ T cells (16 times 
higher) when mice were immunized with NP-SPDP-CSIINFEKL-CpG and NP-SMCC-
CSIINFEKL-CpG as compared to mice receiving a mixture of soluble antigen and adjuvant. In 
case of both the linkers, co- conjugation of adjuvant and antigen resulted in 4-5 times higher 
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induction of IFN- producing T cells in spenocytes as well as 10 times higher induction in WBCs, 
as compared to NPs conjugated  
 
 
Figure-4.8: Induction of IFN- producing SIINFEKL specific CD8+ T cells in a) spleen and 
b) circulating blood.  
Mice were immunized with various samples containing 100 µg peptide and/or 20 µg CpG via s.c 
injection in left flank. One week later, splenocytes and WBCs were isolated and re-stimulated with 
SIINFEKL for 20 h for IFN- ELISPOT assay, a) splenocytes and b) WBCs. Results are shown as 
mean ± SD, n=4-9. Data were analyzed by one-way anova, Holm-Sidak’s multiple comparison 
test, *p < 0.05, *** p < 0.001.  
 
to antigen alone. IFN- producing T cells response was minimum in case of negative control-blank 
PRINT NPs as well as in untreated mice. Despite the different design and antigen release profile, 
in this 7 day study, there was no observed difference in induction of CD8+ T cells between the NP 
formulations. 
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4.3.7 Protection against tumor growth- EG7 mouse tumor model 
 
Figure-4.9: Tumor 
growth challenge 
study. C57BL/6 mice 
were vaccinated with 
prime dose and booster 
dose on day   -28 and day 
-7, respectively. On day 
0, seven days after 
booster dose, 9.3 x 
105EG7 cells were 
subcutaneously injected 
in the left flank (opposite 
side of vaccination). 
Tumor growth was 
measured by the Animal 
Core Facility. All the 
mice were euthanized 
humanely once 
untreated mice were 
reached tumor burden 
i.e. 20 mm in 
measurement in either 
dimensions. Mice 
vaccinated with the PEG hydrogel subunit vaccine has significantly inhibited EG7-OVA tumor 
growth as compared to the untreated mice, and mice treated with soluble peptide + soluble CpG. 
Moreover, 14 days after tumor cells implantation, all 7 mice treated with the non-cleavable linker 
vaccine have total inhibition of tumor growth. Data were analyzed by two-way ANOVA followed 
by Bonferroni’s post-test. *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001. 
 
To determine how the induction of IFN-γ producing CD8+ T cells in mice would translate 
to protection against tumor growth the subunit vaccines were evaluated in a tumor challenge 
study. C57BL6/J mice were either kept untreated, or vaccinated with either a mixture of soluble 
CSIINFEKL and soluble CpG dissolved in sterile water, or with NP-SPDP-CSIINFEKL-CpG, or  
with NP-SMCC-CSIINFEKL-CpG on day -28. A booster dose was given on day -7. Seven days after 
the booster dose, on day 0, mice were inoculated with ~106 EG7.OVA thymoma cells in the right 
flank (opposite side of vaccine administration). Tumor growth was measured as mentioned in 
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method section throughout the study. As shown in Figure-4.9, untreated mice and mice treated 
with the mixture of soluble peptide and CpG started developing tumors on day 3,  
 
Figure-4.10: Evaluation of antigen specific IFN-
γ producing CD8+ T Cells  
On day 20 mice were euthanized and SIINFEKL 
specific IFN-γ producing T cells (from spleen) 
were evaluated via ELISPOT assay. Induction of 
IFN-γ producing CD8+ T cells is significantly 
higher in mouse treated with non-cleavable sub-
unit vaccine as compare to untreated mice and 
mice treated with other formulations. Data were 
analyzed by Student’s T test. *, p<0.05. 
 
 
 
 
 
while mice vaccinated with NP-SPDP-CSIINFEKL-CpG exhibited inhibition of tumor growth 
until day 7. Interestingly, all mice vaccinated with NP-SMCC-CSIINFEKL-CpG experienced 
tumor inhibition until day 14. Furthermore, to evaluate whether delayed tumor growth was due 
to higher induction of CD8+ T cells, we isolated splenocytes at the end of the study and analyzed 
IFN-γ producing CD8+ T cells via ELISPOT. We found that frequency of IFN-γ producing CD8+ T 
cells was higher in mice vaccinated with NP-SMCC-CSIINFEKL-CpG as compared to the other 
formulations (Figure 4.10). Results from these studies further conclude that CSIINFEKL and CpG 
co-conjugated to NP via SMCC provide better protection against tumor challenge as compared to 
conventional disulfide linked subunit vaccine.  
 
 
 
89 
 
4.4 Discussion 
Previously we have shown induction of potent CTLs by co-delivery of SIINFEKL and CpG 
through hydrogel NPs. Here we further demonstrated induction of CSIINFEKL specific IFN-γ 
producing CD8+ T cells as well as protective antitumor immune response in EG7 tumor mouse 
model by delivering formulations of CSIINFEKL and CpG ODN via PRINT hydrogel NPs that 
enable sustained release of cargos. We observed different peptide release rates for peptides bound 
to NPs via either a disulfide or thioether linkages.  The disulfide linkage was rapidly cleaved, and 
peptide release reached a maximum at 1 hour in 10 mM GSH, whereas peptide bound through the 
thioether linkage was released more slowly, with the maximum peptide release at 8 hours. These 
release rates were able to effect in vitro BMDC antigen presentation over time when antigenic 
peptide is conjugated, as well as production of IL-6 when CpG is conjugated.  We observed that 
BMDCs treated with CSIINFEKL conjugated NPs linked via thioether linker had a higher and 
prolonged antigen presentation as compared to BMDCs treated with disulfide linked CSIINFEKL. 
While both formulations induced maturation of BMDCs and prolonged the release of IL-6, the 
effect was higher in cells treated with CSIINFEKL conjugated NPs via thioether linker. 
Furthermore, the peptide release kinetics resulted in differences in tumor protection in vivo.  Mice 
treated with either formulation had significantly lower tumor growth as compared to mice treated 
with soluble CSIINFEKL and CpG, however, due to the more stable and controlled release of 
CSIINFEKL from thioether linked NP formulation, tumor growth was controlled for up to 14 days, 
versus only 7 days for the disulfide linked NP formulation.   
These results are in agreement with recent literature showing how vaccine formulations 
with prolonged release of antigen have higher chance of inducing stronger and persistent immune 
response [32, 33]. The initial and following availability of antigen and/or adjuvant could be 
important for generation of desired immune response. Compared to soluble vaccine components, 
nanoparticle-mediated delivery can provide much better control over release kinetics and bio-
distribution of their cargos in lymphoid tissues upon immunizations. Controlled release of antigen 
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has been achieved by encapsulating antigen into different polymeric nano-microparticles, [34] 
which resulted in higher and more persistent antibody titers. These carrier systems have been 
reviewed elsewhere [35-37]. Though these results were promising, it has not been evaluated 
throughout the literature how extended release translates to induction of CTL response for the 
treatment of cancer.  
In our nanoparticle-based vaccine formulations, sustained release of CSIINFEKL peptide 
was achieved up to 3 days by conjugating to NPs via thioether linkers, in a reducing environment. 
Release profile of CSIINFEKL from NPs could be different in intracellular environment due to 
presence of many other variables such as peptidases, thioredoxin etc.  Disulfide linked 
CSIINFEKL had initial burst release from NPs but thioether linked CSIINFEKL provided more 
stable and prolonged release of peptide. Baldwin and Kiirck had shown that N-ethylmaleimide 
can undergo exchange reaction with presence of other thiols such as glutathione when conjugated 
to 4-mercaptophenylacetic acid (MPA), N-acetylcysteine, or 3-mercaptopropionic acid (MP). The 
half-life of glutathione-maleimide adduct formation were dependent of reactivity of Michael 
donor [19]. Moreover, thiol exchange can be attenuated by designing self-hydrolyzing maleimide 
[21]. Therefore, by changing the Michael donor’s reactivity or by designing self-hydrolyzing 
maleimide linkers, we could further tune the release of antigenic peptide and thus in vivo immune 
response.  
CD4+ T cells assist in generation of functional and protective CD8+ T cells as well as 
antibodies through B cells [38]. They directly interact with CD8+ T cells via CD40 ligand to boost 
the CD8+ T cells response. Also help from CD4+ T cells is required for generation of memory CD8+ 
T cells [39]. Immunization of mice with whole ovalbumin protein conjugated pluronic stabilized 
polypropylene disulfide (PPS) NPs induced stronger CD4+ T cells, CTLs and effector memory 
response in mice with EG7 and B16F10 tumor [9, 10]. Although whole protein delivery induces 
CD4+ T cells to boost CTLs, synthesis and large scale manufacturing of tumor antigen proteins is 
a big challenge. In this study we have focused on CD8+ T cell epitope peptides for generating CTLs 
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and have demonstrated the efficacy for the system. We anticipate that using similar conjugation 
strategies, MHC-II epitope peptides can be easily associated to NPs and co-delivered with CTLs 
epitope peptides to induce CD4+ T cell help to boost CD8+ T cellresponse and memory. The 
nanoparticle platform provides an ideal setting for delivery of multiple peptides concurrently on 
same particle, or different epitopes on different nanoparticles. These are currently being explored 
with tumor associated antigenic peptides. 
4.5. Conclusion 
Here we have designed controlled release delivery system to deliver CSIINFEKL and CpG 
ODN by conjugating them to hydrogel NPs either via disulfide (SPDP) or thioether (SMCC) 
linkers. CSIINFEKL linked to NPs via thioether linker provided stable and sustained release as 
compared to rapid release when conjugated via disulfide linker. Both formulations were 
successfully internalized and processed by BMDCs, resulting in BMDC maturation, subsequent 
cross-presentation of antigenic peptide, and induction of IL-6 secretion. Thioether linked 
CSIINFEKL and CpG ODN resulted in stronger and prolonged effect on BMDCs maturation, 
secretion of IL-6, and antigen cross-presentation. Both formulations significantly inhibited EG7 
tumor growth in mice, however, co-delivery of CSIINFEKL and CpG ODN via thioether 
conjugated NPs resulted in 2 times stronger antitumor efficacy as compared to disulfide linked 
CSIINFEKL and CpG. Taken together, this study provides a highly effective approach to induce 
antitumor immunity by tuning the release of antigenic peptide via changing the conjugation 
chemistry. 
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Chapter-5: Future Directions and Summary 
5.1. Future directions 
Here we have shown that intracellular delivery of antigenic peptides and adjuvants by 
particulate subunit vaccine induced potent CTLs as well as provide a protective response against 
tumor growth. By varying the nature of linker used in the conjugation process we can provide 
sustained release of conjugated antigen resulting in higher antigen cross-presentation, 
maturation of DCs, induction of IL-6, and better protective immune response. In this section, I 
am discussing different strategies to optimize subunit vaccines to develop a better immune 
response to combat cancer.  
One of the parameters that we could study is the density of antigens or adjuvants on the 
surface of nanoparticles. Better subunit vaccines can be designed by understanding the optimum 
density of antigen required to produce a maximum immune response. Reuter et al. has shown the 
significance of ligand (antibody / affibody) density on the surface of particles for their 
internalization, biodistribution, and tumor uptake [1]. Little S. has pointed out the importance of 
multivalent ligand display in particulate vaccine design. Plasmodium Vivax, a malarial parasite, 
displays antigenic protein circumsporozoite protein (CSP) and structure similar to TLR-4 agonist. 
As shown in figure 5.1, when B cells come in contact with this parasite, multivalent binding of CSP 
and TLR-4 agonist to B-cell receptor (BCR) induce clustering of B-cells via cross-linking of BCRs. 
This natural multivalent binding is capable of inducing potent and persistent humoral response 
[2]. Moon et al. was able to generate a better suited antibody response against malaria by 
delivering CSP protein antigen and TLR-4 agonist MPL-A (monophosphoryl lipid-A) via novel 
multilamellar lipid vesicle delivery system (ICMV), than when antigen and MPL-A was delivered 
in a soluble form [3]. Homhuan et al. showed that decreasing the protein density from virosome 
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surface (envelope proteins of Newcastle disease virus (NDV)) failed to induce serum 
haemaglutinin-inhibition (HAI) antibody titers, possibly due to loss of highly organized viral 
surface structure [4]. PRINT provides us an ideal platform to precisely control surface density of 
antigens and adjuvants via various conjugation strategies. As mentioned in chapter-3 and 4, 
different linker chemistries can be used to tune the release of conjugated antigens. By 
controlling the antigen and adjuvant density on the surface of the NP we could further control 
the uptake of subunit vaccine to DCs and thus potentially maximize the cross-presentation and 
cellular immune response.  
Figure-5.1: Multivalent display of antigen and TLR4 agonist to an antigen presenting cell 
(APC) such as a B cell by a malarial sporozoite and a nanoparticle/adjuvant formulation.  
P. vivax displays circumsporozoite proteins (CSP) prominently on its surface, as well as 
structures that likely serve as TLR4 agonists (12, 13). Clustering of B-cell receptors is achieved 
as a result of the natural, repetitive display of the CSP. This combination of persistent, 
multivalent antigen presentation in context with particular, parasite-associated “danger signals” 
would be recognized by the immune system in a way that would produce immune responses that 
are well-suited to combat the parasite. (B) Synthetic ICMVs [as described in [3]] can be designed 
to display a subunit CSP antigen (VMP001) through both sustained release and multivalent 
presentation on their surface. When administered along with the TLR4 agonist MPLA, these 
nanoparticles produce an immune response that is better suited to combat malaria than when 
antigen and conventional adjuvant are delivered alone. Figure and caption are reprinted from [2] 
PNAS, Vol 109, Issue 4, Steven R. Little; Reorienting our view of particle-based adjuvants for 
subunit vaccines, 999-1000, Copyright (2012), with permission from PNAS. 
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As discussed in the chapter-2 size of the naoparticulate carriers plays a very important 
role in controlling the immune response. Size of the NP carrier is known to influence their 
uptake, lymphatic drainage and extracellular trafficking. Smaller size particles of <100 nm drain 
directly to the lymph nodes and penetrate deeper into lymph node to interact with immature 
DCs, B-cells and T cells [5, 6]. Many have shown better lymphatic trafficking [7], better humoral 
response as well as stronger antitumor immunity by smaller sized particle (40 nm) as compared 
to bigger sized (100 nm) [8]. PRINT platform provides us an unprecedented control over 
particle size to fabricate various size of particles ranges from 50 nm to 3 µm. For future studies, 
subunit vaccine can be redesigned by utilizing smaller size particle such as 50X60 nm. Different 
sizes of PRINT hydrogel subunit vaccines can then be compared for their lymphatic trafficking, 
uptake by APCs, antigen cross-presentation and in vivo induction of CD8+ T cells. Smaller size 
particles could possibly increase their lymphatic uptake and could increase induction of CTLs. 
For future vaccine design, MHC-II epitope peptide can be co-delivered with MHC-I 
epitope peptide to induce CD4+ T cells to boost CD8+ T cells response and to create memory 
response. CD4+ T cells assist in the generation of functional and protective CD8+ T cells as well 
as antibodies through B-cells [9]. They directly interact with CD8+ T cells via CD40 ligand to 
boost the CD8+ T cells response. If CD8+ T cells are primed in presence of CD4+ T cells, CD8+ T 
cells go through a second round of clonal expansion once re-stimulated again in absence of CD4+ 
T cells [10]. To this point, Titta et al. found that delivering MHC-II epitope with MHC-I epitope 
in form of whole protein induced potent CTLs and memory response. Immunization of mice 
with whole ovalbumin protein conjugated pluronic stabilized polypropylene disulfide (PPS) NPs 
induced stronger CD4+ T cells, CTLs and effector memory response in mice with EG7 and 
B16F10 tumors [11, 12].  Although whole protein delivery induce CD4+ T cells to boost CTLs, 
synthesis and large scale manufacturing of tumor antigenic peptide is the biggest challenge. 
Immunogenicity from unknown components of whole proteins and safety is also concern. Not 
many studies have been performed to evaluate the help provided from MHC-II epitope peptides 
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in the generation and persistence of CD8+ T cells via particulate vaccines.  Mansour et al. has 
significantly inhibited the growth of tumor in B16F10 melanoma mice model byo-delivery of 
helper peptide PADRE (pan DR epitope-AKXVAAWTLKAAA-OH) with Trp-2: 181-188 
(VYDFFVWL) and p-53: 232-240 (KYICNSSCM) [13]. Due to advancement in the field of cDNA-
expression cloning techniques and the use of autologous antibodies to identify peptides of TAA, 
large numbers of peptide epitopes for many tumor antigens can be synthesized. Multivalent long 
peptide vaccines (with extra flanking amino acids) or hybrid peptide vaccines (consisting of CTL 
and helper peptide epitopes) or peptide cocktail vaccines (mixture of MHC-I epitopes of 
multiple antigens) have been evaluated in clinical trials resulted into moderate to robust 
immune response [14-16]. Delivering such peptides via particulate subunit vaccine should be 
considered to design better vaccines. Future PRINT subunit vaccine could contain multiple 
antigenic peptide epitopes on the same particle or a mixture of different NPs conjugated to 
separate MHC-I and MHC-II helper epitopes.  
Moreover, different intracellular receptors such as TLRs, NLRs (nod like receptors), 
RIG- I like receptor (retinoic acid inducible gene I like receptor), STINGs (DNA sensors, 
Stimulators of interferon genes) etc. which recognize different ‘danger signals’ from pathogen 
associated molecular patterns (such as unemthylated DNA from bacteria or viruses, bacterial 
coat proteins and lipids etc) can be simultaneously stimulated by delivering multiple immune 
stimulating agents and/or agonists such as CpG ODN (TLR-9 agonis), resiquimod and 
imiquimod (agonist of TLR-7/8), muramyl dipeptide (agonist of NOD2), cyclic dinucleotides 
(agonist of STING) etc. Single or multiple aduvants can be co-formulated with antigens to 
enhance immune response. Co-delivery of TLR7 agonist R837 and TLR4 agonist, MPL-A in 
PLGA NP with HA protein, synergistically increased antigen specific neutralizing antibodies in 
mice as compared to NP containing antigen plus single TLR ligand [17]. Furthermore, it was 
reported that immunization of mice with NPs containing antigen and two adjuvants, protected 
mice completely against lethal avian and swine influenza virus strains, and induced robust 
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immunity against pandemic H1N1 influenza in rhesus macaques [17]. Additionally, Napolitani et 
al. found that agonist of TLR3 and TLR4 potently synergize with agonist of TLR8 and induced 
50-100 times higher secretion of IL-12 and IL-23 as compared to single TLR agonist [18]. 
Furthermore, co-delivery of TLR4 agonist glucopyranosyl lipid adjuvant-stable emulsion (GLA-
SE) and TLR-9 agonist CpG ODN with mycobacterium tuberculosis antigenic protein ID93 
synergistically induced Th1 type protective immune response in mice [19]. PRINT NPs can be 
used to study the synergistic effect of multiple adjuvants with antigens. As shown in chapter-3 
and 4, adjuvant effect of CpG significantly increased the numbers of IFN- γ producing CD8+ T 
cells. Future PRINT subunit vaccine design could include multiple adjuvants to further induce 
production of multiple cytokines via activating many intracellular PRRs, which could decrease 
the dosage and frequency of vaccine administration and increase the speed and duration of 
immune response. 
5.2. Summary 
 As discuss earlier (chapter-1) induction of high frequency of potent CTLs response and 
inhibition of immunosuppressive tumor environment are necessary to achieve successful 
immune response in fight against cancer. Although, different types of cancer vaccines have 
achieved lot of success in pre-clinical and clinical trials [20-22] due to generation of durable, no-
toxic antitumor immune response, immunosuppressive tumor microenvironment is the biggest 
hurdle making clinical translation of cancer vaccines difficult. The ability to block key pathways 
by which tumor cells seek to evade or suppress the immune response is critical to realize the full 
potential of cancer vaccines. In 2010, FDA approval of ipilimumab (an antibody against CTLA-
4) has changed the landscape of immunotherapy research and provided new promise for cancer 
treatment. Since then many other immunotherapies have been approved by FDA such as 
blinatumomab (Blincyto®, a novel class of bispecific T cell engagers, which consists of two 
monoclonal antibodies, one binds to T cells and another binds on cancer cell and induce killing 
of cancer cell) for use in the treatment of B cell acute lymphoblastic leukemia, PD-1 inhibitors 
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pembrolizumab (Keytruda® made by Merck) and nivolumab (Opdivo® made by Bristol-Myers 
Squibb) for the treatment of lung cancer and talimogene laherparepvec (Imlygic™ made by 
Amgen) for the treatment of advanced melanoma [23]. Successful elimination of tumors can be 
achieved by combining cancer immunotherapy to revert the immunosuppression to boost the 
effect of T cells and NK cells with cancer vaccine to induce potent immune cells against multiple 
tumor antigens. Optimizing the effectiveness of cancer vaccine will require targeting the 
antitumor immune response at multiple levels, and this may be achieved through synergistic 
combinations. Examples include combining immune checkpoint inhibitors or epigenetic 
immune modulators with cancer vaccines, or by combining chemotherapy and cancer vaccines 
with targeted drug delivery vehicles carrying inhibitors/modulators of immunosuppressive 
TME. Recently, pre-clinical and clinical studies have been done incorporating combination of 
cancer vaccine with immunotherapies which includes combination of OX40 ligand, anti-CTLA4 
and Her2 vaccination; PD1 blockade with CTLA4 blockade; nivolumab in combination with 
GM.CD40L vaccine; combination immunotherapy of GM.CD40L vaccine with CCL21; etc. 
resulted into synergistic antitumor response which was better as compared to cancer vaccine or 
immunotherapy alone [24-29].  
Combination strategies with immunotherapy have provided cancer patients with novel 
treatments that have the potential to elicit durable control of disease and improvement in 
quality of life. The ability of an activated immune response to generate: 1) a diverse T cell 
repertoire that adapts to heterogeneous and genetically unstable tumors, 2) persistent memory 
T cells with specificity for tumor antigens, which provide efficient recall responses against 
recurrent disease, and 3) re-establish the “normal cellular environment” make it absolutely 
essential to expand our efforts to find rational combinations to unleash antitumor immune 
responses for the benefit of cancer patients. We are revealing the complex regulatory 
mechanisms that enable cancer to escape immune surveillance and develop into our worst 
nightmare. Therefore, as the scientific community continues to investigate and learn about 
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highly complex and dynamic system that is cancer, we must also continue to assess the 
effectiveness of an evolving immune response, define the immune response that contributes to 
clinical benefit, and then, hopefully, drive every patient’s immune response to combat their 
cancer most effectively. Properly done, it seems likely that more effective treatments and/or 
cures for many types of cancer will become reality. 
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APPENDIX 
 
 
Figure-1: Total ion chromatogram (TIC) of supernatant from A) NP-SPDP-CSIINFEKL (0.5 
hours) and B) NP-SPDP-CSIINFEKL (48 hours). Individual mass-spectrum of each species is 
shown in figure-2 and 3. 
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Figure-2: Mass- spectrometry analysis. (A-D) Intensity vs m/z for each species of supernatant 
from NP-SPDP-CSIINFEKL (48 hours) 
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Figure-3: Mass- spectrometry analysis. (E-H) Intensity vs m/z for each species of supernatant 
from NP-SPDP-CSIINFEKL (48 hours) 
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Figure-4: Total ion chromatogram (TIC) of supernatant from A) NP-SMCC-CSIINFEKL (0.5 
hours) and B) NP-SMCC-CSIINFEKL (48 hours). Individual mass-spectrum of each species is 
shown in figure-5 (A-G) 
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Figure-5: Mass- spectrometry analysis. (A-D) Intensity vs m/z for each species of supernatant 
from NP-SMCC-CSIINFEKL (48 hours) 
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Figure-6: Mass- spectrometry analysis. (E-G) Intensity vs m/z for each species of supernatant 
from NP-SMCC-CSIINFEKL (48 hours) 
 
